Proxy genotypes and phenotypes for human genetics by Yelensky, Roman
Proxy Genotypes and Phenotypes for Human Genetics
by
Roman Yelensky
M.S. Computer Science, Stanford University, 2003
B.A. Computer Science, Cornell University, 2000
SUBMITTED TO THE DIVISION OF HEALTH SCIENCES & TECHNOLOGY IN
PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY IN
BIOINFORMATICS AND INTEGRATIVE GENOMICS
AT THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
SEPTEMBER 2008
Copyright 2008 Massachusetts Institute of Technology. All rights reserved.
Signature of Author:
Harvard-MIT Division of Health Sci'nhces & Technology
August 4 th, 2008
Certified by (Thesis Supervisor):_
Harvard Medical
Certified by (Co-Advisor):
David Altshuler MD, PhD
Professor of Genetics and Medicine
School, Massachusetts General Hospital
( AMark Daly, PhD
Assist rit Professor of Medicine
Harvard Medical School, Massachusetts General Hospital
Accepted by:
Martha Gray, PhD
Edward Hood Taplin Profissor o Medical and Electrical Engineering
Director, Harvard-MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology

Proxy Genotypes and Phenotypes for Human Genetics
by
Roman Yelensky
Submitted to the Division of Health Sciences & Technology on August 8t , 2008 in
Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in
Bioinformatics and Integrative Genomics
Abstract
Genetic mapping by association is an unbiased approach to discover genes and pathways
influencing disease traits and response to drugs and environmental exposures. There are
two key obstacles to mapping in humans: (1) The full sequence of study subjects cannot
yet be obtained; and (2) There are substantial limits to the phenotypes that can be safely
elicited or measured. Geneticists thus rely on practically measurable sets of genotypes to
proxy for the sequence and human in-vitro models that proxy for in-vivo genetics and
physiology while allowing for perturbation and characterization in high throughput. This
thesis presents the development of one important class of proxy genotypes, those that
capture most common genetic variation, as well as an evaluation and refinement of proxy
phenotypes offered by one commonly used in-vitro model, the lymphoblastoid cell-line.
Capturing common human genetic variation for genome-wide association studies requires
genotyping a feasible subset of proxy (or "tag") SNPs. We investigated selection and
analysis of tag SNPs, examined the relationship between investment in genotyping and
statistical power, and evaluated whether power is compromised when tags are selected
from an incomplete resource such as HapMap. We demonstrate an efficient haplotype-
based tagging approach and other methods that dramatically increase tagging efficiency.
Examining all observed haplotypes for association increases power to detect rare causal
alleles, while reducing power for common alleles. Power is robust to completeness of the
reference panel and holds across demographically related groups.
Lymphoblastoid cell lines (LCLs) are being developed into an in-vitro model where
genetics of human gene expression, drug response, and other traits can be studied under
controlled conditions. However, the impact of the immortalization process, the relative
influence of non-genetic factors, and reproducibility of measured traits are not yet
understood. We addressed these questions while mapping loci for response to
chemotherapy and found that traits in LCLs are subject to substantial confounders and are
only modestly reproducible in independent experiments. Despite this, RNA expression of
many genes is affected by genetic variation and predicts response to drugs; integrating
SNPs, RNA, and drug response can identify novel pharmacogenetic variation mediated
by RNA.
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Co-Advisor: Mark Daly, PhD
Title: Assistant Professor of Medicine, Harvard Medical School
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Chapter 1: Introduction
Much of the progress of biomedical science over the last several hundred years
can be viewed as the gradual refinement of gross phenotypic observations of anatomy
and disease into a detailed mechanistic description of organ, tissue, and cellular
functions, inter-relationships, and pathophysiology. The tools and methods of molecular
biology developed over the last few decades now open the "final frontier" of this advance
and make possible a detailed understanding of how bio-molecules interact to produce
behaviors at every level of aggregation above. When this frontier is sufficiently explored,
an integrative view of human biology can emerge that will revolutionize pharmaceutical
development and the practice of medicine. The scientific questions framing and
motivating this research often focus on the study of differences: Why do some develop
heart disease and others do not? What changes a previously healthy tissue to diseased?
Why are some fatally susceptible to infection, while others are immune? Uncovering the
molecular basis of this phenotypic variation is thus one of the great undertakings of
biomedical research today.
A major component of this enterprise is the investigation of inherited genotype-
phenotype relationships, or genetics. The existence of tremendous natural, heritable
variation in most traits of interest, coupled with the current detailed understanding of the
molecular mechanisms of inheritance makes fertile ground for scientists interested in how
molecular changes lead to differences between whole organisms and what happens at
every level in-between. For example, the most practical first step in understanding
unknown biology of a disease is often the genetic mapping of susceptibility or risk,
followed by identification of the mutations responsible and characterization of the role
implicated genes play in pathophysiology. Genetic discoveries can often lead to disease
prevention (i.e. Tay-Sachs), more effective treatments (cystic fibrosis 1), and may even
hold promise for cures. A complementary application of human genetic research is the
study of natural variation in drug toxicity and response. Identification of genetic variants
resulting in impaired drug metabolism have lead to screening tests that prevent
substantial morbidity/mortality associated with standard treatments for a variety of
conditions (i.e. 6-mercaptopurine for leukemia and inflammatory bowel disease 2
abacavir for HIV 3). Further research will help explain differences in efficacy 4
encountered with commonly used drugs and suggest new pathways and targets for
pharmacologic development.
For several decades, human genetic research was carried out using the linkage
approach (pioneered by Morgan and Sturtevant for drosophila 5) with sparse collections
of markers throughout the genome for overt clinical phenotypes demonstrated by severe
mendelian disorders 6. While the approach clearly made tremendous contributions in
uncovering the genetic basis of rare conditions such as Huntington's disease, it generally
fell short when applied to common, complex, though still heritable, conditions such as
obesity, diabetes, or cardiovascular disease. 7-9 Among the many reasons linkage was less
effective was its relative lack of statistical power to detect common variants of modest
effect 10, locus heterogeneity, and the inherent difficulties in fine-mapping causal genes
from wide linkage peaks. Most importantly, the key assumption on which the success of
linkage rests, that disease is caused by high penetrance alleles in few genes, appeared to
not hold for most traits. On the phenotype side, investigators have traditionally been
limited to low-throughput, limited scope physical exam, history, clinical chemistry and
pathology, making determination of mechanism difficult and time consuming (or
impossible) even if the causal variant could be found.
To clarify next steps necessary to overcome these obstacles and realize the full
promise of human genetic research for all heritable traits, it is helpful to imagine what the
"best case" scenario for a human geneticist would look like. Aside from the usual desire
of infinite sample size, clearly we would like to have the full sequence of every
individual under study, preferably combined with a genome-wide understanding of
epigenetic and other relevant genome variation. On the phenotype side, we would like to
know the RNA expression, post-translational modifications, and intra-cellular
localization of every gene in every cell in the body, the expression and activation state of
every cell-surface receptor, as well as complete proteomic and metabolomic
measurements in all extra-cellular compartments. Finally, to understand variation in drug
toxicity and response, we would like the ability to harmlessly dose any study subject with
any drug or toxin and measure relevant changes in physiologic state.
While some of these requirements may conceivably be within reach (like full
sequence), others are still quite far off (such as detailed proteomic measurements of
remote compartments), and the ability to safely give any person any drug for the sake of
genetic research will likely never be attained. Nevertheless, how close we can get to
these goals will define how much we can learn from human genetics (and, indeed, from
biomedical research in general!) This thesis presents the development of analytical and
experimental tools and resources that moves us towards this "best case", while expanding
the horizons of discoveries possible right now.
Recent advances in sequencing and genotyping technology, as well as significant
investment, have given us an unprecedented understanding of the human genome and
genetic variation 11, and with it the capability to search for the genetic basis of complex
traits using the association approach. 12 At the same time, -omic tools such as RNA
micro-arrays have broadened and deepened our conception of "phenotype." 13 Histology
based cancer staging being enriched by detailed expression profiles 14, and classical
definitions of diabetes being supplemented by detailed views of the dysregulated
pathways 15, are just two of a myriad examples. This confluence of genotypic and
phenotypic advances opens exciting avenues for progress 16 in understanding the links
between genes and traits and every step in-between; however, substantial practical
obstacles and open methodological questions in the application of these tools remain.
On the genotype side, the 3GB human sequence still far dwarves our ability to
measure it routinely in more than a handful of individuals; full re-sequencing genetic
mapping experiments are still likely several years away. Even the millions of markers
(SNPs) 17 of human variation that have recently become available are beyond present-day
financial and technological means. An even more important challenge is that unlike
model organisms that can be exhaustively phenotyped and readily exposed to drugs and
toxins in the laboratory, there are substantial limits to the phenotypes that can be safely
elicited or measured in human subjects. Geneticists thus rely on practically measurable
sets of genotypes to proxy (as well as possible) for the full sequence and human in-vitro
models that can proxy for in-vivo genetics and physiology while allowing for systematic
perturbation and characterization in high throughput.
This thesis presents the development of one important class of proxy genotypes,
those that capture most common genetic variation, as well as an evaluation, refinement,
and application of proxy phenotypes offered by one commonly used in-vitro model, the
lymphoblastoid cell-line. The section titled "Proxy Genotypes: Capturing common
genetic variation" below offers a detailed introduction and historical background to our
treatment of the genotype challenge, contained in Chapters 2-5. The following section,
titled "Proxy Phenotypes: Genetic analysis of human traits in-vitro", likewise reviews
the context for the phenotype challenge, addressed in full in Chapter 6. We then recap
with a roadmap for the reader to follow, before diving in and exploring the material in
depth.
Proxy Genotypes: Capturing common genetic variation
In an influential perspective published in Science in 1996 10 and soon echoed by
other '8, Risch and Merikangas argued that the path forward for uncovering the genetic
basis of common, complex human diseases lay with the genome-wide association, and
not the linkage, approach. Linkage uses sparse marker genotypes throughout the genome
to identify shared chromosome segments in closely related affected individuals and then
aggregates this information over many families to detect increased sharing in particular
(hopefully small) regions of the genome. This region is then hypothesized to harbor a
causal mutation for the disease. Association, in the case-control formulation, counts
alleles at a potentially causal polymorphic site in unrelated cases (affected) and controls
(unaffected) and declares association if there is statistically significant enrichment in
either set. 12 In it's transmission disequilibrium form, association counts transmissions of
an allele from heterozygous parents to affected offspring and declares success if there is
significant over- (or under-) transmission of the allele. The authors demonstrated that
association (because it tested the polymorphism directly) was a more statistically
powerful approach and, in particular, that association can detect variants of modest effect
suspected of having an important role in common disease at attainable sample sizes,
whereas linkage could not.
A crucial assumption and key criticism of the above analysis was that the
polymorphism evaluated for association was the causal site itself. It was pointed out
immediately 19 that power would fall dramatically if the polymorphism evaluated for
association with the disease trait was not in strong linkage disequilibrium (non-random
association of alleles in unrelated individuals) with, or substantially differed in frequency
from, the causal mutation. It was generally understood that genome-wide catalogues of
variation available at the time (libraries of 100s or 1000s RFLPs or microsatellites), while
adequate for capturing recombination events in families for linkage scans, would not be
linked tightly enough (or at all) to most possible causal mutations for association to work.
Thus, calls were issued for the creation of much larger catalogues of human genetic
variation that may contain many putative causal alleles directly (i.e. coding changes), and
be potentially dense enough to detect association indirectly through linkage
disequilibrium (LD) with most others. 20
These calls were answered by several efforts, most notably by groups
participating in the ongoing Human Genome Project and the newly formed SNP
Consortium. 17,21 The genome project confirmed previous estimates 22 that humans were
identical at >99.9% of their sequence and that by far the most abundant class of variation
in the human genome were single nucleotide polymorphisms (or SNPs); any two
genomes differed at -8 SNPs for every 10 kilobases of sequence. The first genome-wide
map of 1.4M SNPs, derived from overlapping reads from large-inset clones and shotgun
sequences from a panel of individuals was published along-side the consensus genome in
2001 and was hailed by human geneticists as an equally (if not more) important
accomplishment 23-25. Despite this impressive advance in increasing the density of
genome-wide catalogues of variation by 1000-fold and making >60,000 coding SNPs
available for candidate gene association studies, a crucial questions for medical genetics
remained: Can putative disease causing variants not on the map (still an overwhelming
majority) now be detected indirectly through LD with variants on the map? Practically,
even cutting-edge genotyping technology circa 2001 could only hope to measure on the
order of 1000s variants in the sample sizes required for association scans, so the
relationships between polymorphic sites (LD) would need to be understood (and
technology improved) before well-powered unbiased genome-wide association studies
could be designed and carried out.
While there were many linkage maps that detailed where recombination was
expected to occur during meioses in families, the history of mutation, recombination,
bottlenecks, and drift of all chromosomes present currently in the population (the
determinants of linkage-disequilibrium) was not known genome-wide. If this history was
such that LD extended for only short distances in the genome (as simulations predicted
26), and if most linked polymorphisms were not well frequency matched, then the map
would need to get much denser and more putative causal sites would need to be
discovered and tested for association to disease directly. If, on the other hand, LD was
long and (relatively) distant sites carried correlated alleles, indirect association methods
could be designed to find mutations responsible for common, complex disease.
The effort to understand LD in the human genome took decades and proceeded in
steps, from original studies looking at single exons and genes 27, to bigger regions, to
multiple regions 28, to eventually a genome-wide view. One of the earlier region-wide
SNP-based studies, published in 2001 29, described LD across -100 SNPs in -250
chromosomes in a 500kb region on 5q31; it was noted that variation in the region existed
in 11 10-100kb sized "blocks" of limited haplotype diversity, punctuated by sites of
historical recombination. Most chromosomes in the population indeed appeared to be
mosaics of 2-4 common haplotypes in each block. This study was soon extended, in 2002
30, to a survey of 54 autosomal regions, spanning 13Mb, in 400 total independent
chromosomes from several population groups. The block-like nature of variation was
confirmed, with over half the genome surveyed appearing in blocks with limited evidence
for historical recombination of length >40kb and >20kb in out-of-Africa and African
samples respectively. Again, limited haplotype diversity was observed, with most
chromosomes consisting of 3-5 common haplotypes per block. Just as importantly, a
haplotype framework defined on only a subset of SNPs correlated well with the rest of
variation in the region. Thus, excitement began to build in the field that at least all
common genetic variation was within reach and the International Haplotype Map project
was launched to catalogue common SNPs genome-wide.
The HapMap project consisted primarily of two goals: (1) To obtain an evenly
spaced, densest map possible of SNP with MAF>5% across the human genome and (2)
To obtain all (or nearly all) SNPs with MAF>5% in 10 unlinked 500kb (ENCODE)
regions. Crucially, the project would provide genotypes for these variants in 100s of
individuals so that LD could be assessed. Together, the two components would allow
geneticists to develop tools for the selection and analysis of polymorphisms to test the
common variant contribution to disease and apply these tools genome-wide. Phase 1 of
the project, containing genotypes for IM SNPs - 1 per 5kb - with MAF>5% in 270
people, as well as 18K SNPs - 1 per -300bp - in the 5MB ENCODE subset, was
published in 2005 " and was hailed by some as an "unprecendented gift" for the genetics
community. 31
Indeed, the data offered great promise for those planning candidate-gene and
whole-genome association scans, as well as commercial vendors designing technology to
support these activities. Analysis revealed extensive allelic correlation between common-
variant polymorphic sites, especially in out-of-Africa populations. For instance, in the
CEU panel, nearly 90% of all common SNPs in the fully ascertained ENCODE regions
were strongly correlated (r"2>0.8) to at least one other common SNP, while almost 60%
were strongly correlated to (also termed "proxied for") at least 10 others. Even in the 10-
times sparser Phase 1 map, 75% of SNPs had at least one proxy at a level of r'2>0.8. On
the whole, it became apparent that most common variation in the population could likely
be captured (or "tagged") by genotyping only a fraction of all sites and appropriately
designed methods to select and test these tags for association to disease may yield
substantial statistical power at feasible technological and economic cost.
Therefore, contemporaneously with the development of the HapMap/ENCODE
resource, attention also focused on the development and evaluation of methods to
facilitate its use in association scans. The fundamental challenge facing investigators
attempting GWAS is how to balance statistical power to detect associations with
financial/technological "efficiency" of the study; i.e. how can we get the best bang for
our buck? At the time of HapMap Phase 1 release, it was not possible to genotype all 1M
common variants known in high throughput; even now its not feasible to genotype all
>3M common variants eventually made available by HapMap Phase 2. More importantly,
the majority of variants with MAF>5% are not even known, making it imperative that
tagging/testing methods maximize power to detect all potential causal sites.
A variety of tagging/testing were proposed in support of previous smaller scale
candidate gene association studies and in anticipation of the HapMap resource. These
differed primarily in the treatment of haplotypes: Some argued that tag SNPs be selected
to capture haplotypic diversity and then tested against traits as proxies for the haplotype.
32,33 Others thought that haplotypes be ignored entirely and tag SNP selection simply
focus on capturing as many single snps as possible. 34,35 A compromise approach was
then advanced where some number of snps was genotyped and tested in a multiple
regression framework. 36 One suggestion was even made to test all possible haplotypes
exhaustively, in the hope that undiscovered SNPs could come to the fore. 37 A review and
comparison of the main methods proposed can be found in 38
The availability of the HapMap/ENCODE resource finally allowed a
comprehensive empirical evaluation of key ideas and underlying principles in the
selection and analysis of tagSNPs: Do pair-wise or multi-marker methods maximize
efficiency and power? Should all observed haplotypes be examined for association, rather
than those that are proxies for known SNPs? What is the general trade-off between
investment in genotyping and power to detect effects? Finally, to what extent is power
compromised when tags are selected from an incomplete resource such as HapMap?
The answers to these questions are important at every stage of study design and analysis
and are critical determinants of success.
We examined the questions above using genotype data from the HapMap
ENCODE project, association studies simulated under a realistic genotype-phenotype
causative model, and empirical correction for multiple hypothesis testing; the results are
presented in Chapter 2 39. Our study demonstrated that whole genome association was
practical with straight-forward methods using the HapMap resource and can reasonably
hope to capture most of the genetic information about common variants in a sample of
individuals. An important criticism of the work was our reliance on a single sample (the
HapMap individuals) to both select tag-SNPs and simulate causal variants. Practically,
tags are selected in some reference panel of individuals (such as the HapMap), but then
genotyped/tested in a new disease study cohort. We addressed this issue in Chapter 3 by
repeating the simulation study across multiple samples and found that our conclusions did
not change under this more realistic scenario 40. As many investigators will be using
commercially available genotyping technology, we extended aspects of the analysis to
fixed-marker platforms such as those manufactured by Affymetrix or Illumina, and found
they too capture a significant fraction of common genetic variation; these results are
presented in Chapter 4 41. Finally, in Chapter 5 42, we apply the simulation framework
used in previous chapters to derive an empirical genome-wide significance threshold for
genome-wide scans for investigators to apply when evaluating their study results.
Taken together, the results in Chapters 2-5 show that a tiny fraction (1/100 th of
1%) of the genome can represent (or proxy for) an entire class of genetic variation
(common variants with MAF>5%) and provide excellent relative power to detect
association with disease. Available genome-wide catalogues of variation (i.e. the
HapMap) and simple analytical approaches are thus sufficient to achieve favorable
tradeoffs between power and efficiency in the design and execution of genome-wide
association scans. This optimistic view of the potential success of GWAS appears to
have borne out, with new genotype-phenotype association findings now being published
nearly every week. 43
Proxy Phenotypes: Genetic analysis of human traits in-vitro
Identification of a genetic variant that confers risk to disease or influences another
whole-organism phenotype is, of course, only the beginning of a long process to elucidate
its function, place it in context of other genetic and non-genetic variation, and
understanding the relevant (patho-) physiology. Unless the variant is an obvious coding
mutation in an exon of a well-studied gene, pointing the way to the mechanism by which
it causes disease, it may not be clear how to proceed from a "hit" in a genome-wide scan.
Often, even after extensive fine-mapping, the LD signal cannot be precisely localized to a
gene at all and no "causal" variant is evident. 44 This, in fact, is the result of a GWAS we
might expect for a complex trait influenced by non-coding regulatory variation. More
work must now be done to generate further leads about which genetic polymorphisms are
responsible and exactly how they act.
There are many potential approaches to this challenge, each more or less
applicable depending on the specifics of the GWAS result to follow up. In the minority of
cases where a promising causal variant is suggested by the genetics, transgenic animals
can be made to study genotype-phenotype relationships in depth, with the expectation
(and hope) that findings will carry over to human beings. 45 If no coding or simple
regulatory (i.e. splice site or poly-A tail) mutation is obvious, but the association signal
can be narrowed down to a relatively small region, then other tools such as databases of
transcription factor binding sites 46 may be brought to bear to identify potentially
functional polymorphic sites. In the general case, however, when the exact polymorphism
or even its precise location is not clear after a GWAS, we will need more information
about study subjects than just the sequence and disease status to make progress.
Traditional clinical traits (sometimes also referred to as "endo-phenotypes" in the
genetics literature) can certainly make important contributions to elucidating mechanisms
of disease-risk conferring genetic variation. As one example, recent studies have shown
that SNPs at nine loci raised LDL cholesterol, lowered HDL cholesterol and conferred
greater propensity to cardiovascular events, implicating previously known pathways of
pathogenesis. 47 Similarly, association with disease and an important endo-phenotype can
offer a new perspective on the disease state and associated complications as did variation
in the glucokinase receptor, which turned out to both confer risk to developing diabetes
and affected levels of serum triglycerides. 48 Although many clinical endo-phenotypes are
easily measured and widely available, they suffer from important limitations: They are
likely far removed, both spatially and temporally, from the causal pathophysiological
process. For instance, while reality may be that a regulatory variant in hepatocytes alters
signaling cascades and induces a myriad important changes in the liver that eventually
lead to increased serum LDL and atherosclerosis, measuring only LDL and disease risk
does not get us close enough to untangling what really happened. Clearly, much more
detailed phenotypic measurements will be necessary to leverage genetic discoveries in
the quest to understand pathogenesis and devise targeted interventions.
Indeed, from the point of view of understanding the impact of genetics on disease
intervention (i.e. drug development), the challenges are even greater. There is great inter-
individual variability in response to drugs 49' 50 , some of it undoubtedly genetic, but only a
few of the causal variants are currently known and even fewer are in active clinical use.51
At the same time, genetic variation can have a profound impact on efficacy and safety,
for instance genotyping variants in the TMPT enzyme can be (cost-effectively) used to
adjust 6-mercaptopurine dose in the treatment of leukemia and avoid potentially fatal
myelosuppression events. 2 However, the discovery and characterization of these variants
is impeded by significant ethical and practical concerns: In-vivo response can only be
studied in patients that were prescribed a drug for a necessary indication, and these
patients may vary in many parameters (i.e. dose, diet, age, other conditions, other drugs)
that we cannot control, making sufficiently sized well-matched cohorts difficult or
impossible to assemble and maintain. Moreover, as above, we may not be able to
measure important sub-phenotypes of response, such as expression of P450 enzymes in
the liver, that may be necessary to understand the mechanisms of the variant even if it is
found.
In sum, human geneticists are faced with the challenge that unlike model
organisms that can be exhaustively phenotyped and readily exposed to drugs and toxins
in the laboratory, there are substantial limits to the phenotypes that can be safely elicited
or measured in human subjects. Thus, there would be great value in a human in-vitro
model that faithfully reflects (or "proxies" for) both in-vivo genetics and physiology
while allowing for systematic perturbation and characterization in high throughput.
To address this need, recent work in human genetics has seen a substantial
evolution in the role of lymphoblastoid cell lines (LCLs) from their traditional use as a
renewable source of DNA into an in-vitro model system where the genetics of human
gene expression, drug response, and other traits can be studied under controlled
conditions. LCLs from hundreds of individuals have already successfully been used to
map the genetic determinants of RNA expression. (eQTLs) 52,53 Some of these eQTLs
have even been found to confer risk to disease, including lupus and asthma. 54 55 Attempts
have likewise been made to use LCLs to understand the genetic/genomic basis of drug
toxicity and response. 56 Much larger projects, involving cell-lines from thousands of
individuals and ever-more extensive catalogues of genotype/phenotypes are currently
under way. But, while early promising results have emerged, little has been written about
the impact of the immortalization process and cell culture conditions, the relative
influence of non-genetic as opposed to genetic factors on cellular trait variation, and
reproducibility of measured traits. As LCLs are a potentially important adjunct to WGAS
of human disease and afford opportunities to study the genetics of traits that cannot easily
be assayed in human beings, we set out to address several of the pressing questions above
using LCLs generated by the HapMap project, while also attempting to map novel loci
for response to several commonly used chemotherapeutic drugs.
Our results are presented in full in Chapter 6. In brief summary, we show that: (1)
Drug response in LCLs can be technically well measured, but is subject to substantial
experimental confounders such as baseline growth-rate and metabolic properties of the
cell line (both non-heritable traits) and is only modestly reproducible in independent
experiments. After correcting for these confounders, no loci for drug response emerge in
a GWAS in our sample with genome-wide significance; this observation is consistent
with prior literature. (2) RNA expression in LCLs can likewise be well-measured, but is
also only modestly reproducible, and is significantly affected by levels of EBV titer and
the confounders of drug response above. Despite this, the expression of many genes is
affected by genetic variation (eQTLs), but the effect sizes are usually small. (3) Baseline
RNA expression predicts response to several drugs and an approach that integrates SNPs,
RNA, and drug response can potentially identify novel pharmacogenetic loci acting
through influence on RNA. Overall, our study indicates that it is critical to understand
both non-genetic as well as genetic factors influencing in-vitro trait variation in LCLs.
We offer practical recommendations regarding experimental design and analysis, and
demonstrate suggestive evidence of three novel loci influencing response to drugs
through their effects on expression of RNA.
As the need for functional follow-up of results from WGAS grows and as investigators
branch out to study the genetics of ever-more complex traits, the need for reliable, human
in-vitro model systems to proxy for in-vivo phenotypes will only increase. We hope our
detailed analysis of one such promising model, the LCL, will serve as an important
building block in the quest to create and productively use such models.
To recap, this thesis is comprised of two halves, dealing with each of the two "proxy"
challenges raised above. The first half, consisting of Chapters 2-5 presents my work
(jointly with wonderful colleagues) addressing the first challenge of capturing and testing
common human genetic variation in association studies. Chapter 2 39 describes the
theoretical relationship between a given investment in genotyping and statistical power to
detect association with a common disease trait, as well as offers practical approaches to
optimize this tradeoff. Chapter 3 40 extends the findings in Chapter 2 to realistic scenarios
where marker selection and disease study takes place in different samples. Chapter 4 41
evaluates the statistical power of current-generation genotyping platforms offered by
commercial vendors. Chapter 5 42 then concludes with an estimate of the multiple-testing
burden imposed when all common variants in the genome are tested. The second half of
the thesis, containing Chapter 6, addresses the second challenge by attempting to build
and use in-vitro models for human genetics, where any (observable) trait of interest can
be evaluated in depth, linked to genetic variation, and potentially expose biology not
accessible in human beings. Chapter 7 then offers a summary and discussion, as well as
some reflection on further lines of research. In all, the thesis represents the development
and use of proxy genotypes and phenotypes that we must rely on for genetic discoveries
until we reach the best case scenario imagined above. As the ideal will likely never be
attained, I hope that the findings in this thesis will be useful for some time to come.
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Introduction
Complete genome sequencing offers a comprehensive approach to test all human genetic
variation for association to clinical traits. While routine sequencing of thousands of
genomes remains impractical, it has become possible to test systematically the vast
majority of human heterozygosity that is due to common genetic variations ' 2.
Correlations among nearby variants (linkage disequilibrium, LD) can improve the cost-
effectiveness of such studies3 5, guiding selection of informative "tag" SNPs6, and
providing information about nearby variants not genotyped in disease samples. The
International HapMap Project is a resource that provides empirical genome-wide data to
support such analyses 7'8 (see also Ref. 9).
Given practical limitations on genotyping in patient samples, investigators are forced to
make a number of practical decisions, including: (a) selecting and prioritizing tag SNPs10-
19; (b) deciding which tests of association to perform2 026; and (c) evaluating statistical
significance of putative findings2729 (see Box for terminology). While genotyping a
higher density of tag SNPs increases the fraction of sites captured through LD30, the
quantitative relationship between additional genotyping and increased power in
association studies is not well described. The use of multi-marker haplotypes shifts this
relationship towards greater efficiency 31, but can be a double-edged sword: if haplotype
testing were to increase degrees of freedom or numbers of tests in statistical analysis, it
has the potential to decrease, rather than increase, overall power24. Many studies will rely
on data from the International HapMap Project, which is an extensive but incomplete
inventory of common genetic variation8. Thus, it is critical to understand how tags
selected from HapMap compare in power to those selected from a more comprehensive
resource.
We set out to study the tradeoffs between efficiency and power for different tagging and
testing approaches. Since expected power in disease association studies is the most
relevant figure of merit (as compared, for example, to the distribution of correlation
coefficients (r2) between tag SNPs and untyped variants), we explicitly model disease
association studies. Second, since varying both the density of tag SNPs and statistical
testing procedure can influence the number of statistical tests (and many of these tests are
not independent), we empirically assess significance thresholds. Finally, as results are
intimately dependent on the true properties of human LD - which are not necessarily
well modeled by population-genetic simulations 32 - we perform these evaluations in
empirical (rather than simulated) genotype data from human samples.
BOX: TERMINOLOGY
Variants to be tested for association to phenotype are putative causal alleles.
The hypothesized relationship between alleles and phenotype(s) is termed the genetic
model.
Genotype data used to guide experimental design (tag SNP selection and definition of
statistical tests to be performed) is termed the reference panel; HapMap is one such
panel.
Tags are the subset of variants genotyped in a disease study. SNPs that are not typed
in the study, but whose effect can be studied through LD with a tag, are termed proxies.
Where the correlation between a tag and untyped putative causal alleles is perfect (P =
1.0), we refer to a perfect proxy.
The allelic hypotheses examined for association to disease (based on genotypes of the
tags) are termed tests. A test can simply be the allele of a tag - termed a single-
marker test. Tests based on combinations of tags are multi-marker tests. A specified
multi-marker test examines a particular allelic combination (a haplotype) of multiple
tags based on its observed correlation to a putative causal (untyped) allele in the
reference panel. An exhaustive multi-marker test searches over many or all allelic
combinations of tags in the hope of finding a test that captures a hitherto unseen
putative causal allele.
Results
Disease association studies based on empirical genotype data
We started by creating case-control panels based on empirical genotype data from the
HapMap-ENCODE project8. These ten 500 kb regions were sequenced in 48 individuals
with all SNPs discovered (as well as any others in dbSNP) genotyped in 269 HapMap
samples: 30 trios of the Yoruba in Ibadan, Nigeria (abbreviation: YRI), 30 trios from
Utah, USA, with European ancestry (CEU), 45 Han Chinese from Beijing, China (CHB),
and 44 Japanese from Tokyo, Japan (JPT). This data set contains 16,970 SNPs (one
every -300 bp) with an allele frequency distribution that is near-complete for common
alleles, and is available for download at http://www.hapmap.org.
To simulate a case-control panel, one SNP from this data set was nominated as "causal".
An effect size was calculated so that if this SNP were directly tested in 1,000 cases and
1,000 controls, power would be 95% to achieve nominal P = 0.01. Since our concern
was the relative effect on power of tagging and analysis strategies (rather than absolute
power), and to make it possible to average results over all putative causal alleles, we
fixed the absolute power for each putative causal SNP. Constant power requires minor
allele frequency to be inversely correlated to penetrance: in this model, rare alleles are
assigned a stronger effect than common alleles (Supplementary Fig. 1). This approach
further avoids consideration of uninformative scenarios where power is uniformly high
(such that any tagging strategy might suffice), or non-existent (such that tagging is
irrelevant).
To simulate the case/control studies, chromosomes spanning each 500 kb region were
drawn at random from the phased empirical data, conditional on the genotype and effect
size at the nominated "causal" SNP. This was repeated until 1,000 cases and 1,000
controls were obtained in each panel, and then 25 such panels were created for each
causal SNP. Finally, the entire process was iterated over all SNPs in the data, resulting in
a large collection of case-control panels in which each SNP has an equal chance of being
causal.
Tag SNPs were selected and statistical tests defined from a reference panel under a
variety of scenarios as described below. Association was evaluated for each statistical test
using standard 2x2 chi-square comparisons of cases and controls. The significance
threshold for declaring association was based on the empirical null distribution: the tags
and statistical tests selected in each scenario were examined in a set of null panels (in
which no SNP is causal), with the maximum X2 value exceeded in 1% of null panels
chosen as the threshold to declare a positive result (region-wide corrected P = 0.01). In
the figures we report the proportion of case-control panels in which an association was
detected, averaged over all putative causal SNPs and over all ENCODE regions.
Capturing all sites observed in a complete reference panel
We began by examining the relationship between the number of SNPs genotyped and
statistical power in the best-case scenario: where complete resequencing has been
performed in a reference panel, such that all putative causal alleles have been observed.
In the first instance we examined only common alleles: tags were selected to capture
alleles > 5% in frequency in the reference panel, and the set of putative causal alleles in
the simulations were limited to those present at 2 5%.
Figure 1 shows the distribution of the maximum X2 values under the null and over all
causal panels. While nominal power is set to 95% if each causal site is examined as a
single test, the average power after testing all common sites in each 500 kb region falls to
60% (YRI) and 68% (CEU and CHB+JPT). This decline simply represents the power
loss resulting from an empirical correction for having tested many hundreds of SNPs
within each 500 kb region, with the decline in power tracking with the extent of LD in
each set of DNA samples.
The simplest and most conservative approach to tag SNP selection is to select a subset of
non-redundant SNPs from the reference panel such that every common allele is either
directly genotyped, or has a perfect proxy (r2 = 1.0) among the tags. The reduction in the
number of genotypes required (as compared to testing all common SNPs directly) was
46% (YRI) and 65% (CEU and CHB+JPT) (Figure 2). Of course, since all sites are
perfectly captured, power remains at 100% as compared to testing all common causal
alleles directly. (From this point onward we will report the "relative power" of each
tagging strategy - that is, power under a given tagging/testing strategy as compared to
that obtained by testing all common sites directly.)
We next asked if multi-marker (haplotype) tests can improve the genotyping efficiency,
as proposed elsewherel0,31. Because we were concerned about loss of power due to the
introduction of additional statistical tests, we developed a strategy (see Methods) in
which an identical set of 1 d.f. tests of association are performed, except that we allow a
haplotype of tags to serve as surrogate for an untyped SNP (rather than restricting
statistical tests to genotypes of single tags). That is, if a specific multi-marker
combination (i.e., haplotype of tag SNPs) can serve as an effective proxy for another tag
SNP, then that latter tag need not be included for genotyping. In this method, each single
tag, as well as each specific haplotype defined above, is tested for association. To avoid
over-fitting, we require that the tags in a specified multi-marker test are themselves in
strong LD (LOD > 3.0) to the allele predicted.
Using this tagging procedure in simulated disease association studies as above, we
computed power and the number of tag SNPs required. In comparison to pairwise
tagging, power remains unchanged at 100%, but the number of tag SNPs that need be
genotyped is reduced by another 26% (YRI), 30% (CEU) and 28% (CHB+JPT) (Figure
2). Thus, simply by removing redundancy from the complete set of SNPs in an efficient
haplotype-based manner, we can reduce the genotyping burden by 60-77% while
maintaining complete power.
Increasing efficiency by relaxing thresholds for tag SNP selection
The strategies above require that tags be selected to capture perfectly every common site
observed in the reference panel. To the extent that this is unaffordable, investigators may
be forced to reduce the density of genotyping by relaxing the criteria for tag selection.
Two possibilities we examined are (a) capturing all common alleles, but at a less
stringent r2 thresholdl4, or (b) by choosing to capture only a subset of sites, each at a high
r2 threshold.
For example, relaxing the threshold from perfect correlation to a slightly lower level (r2
0.8) decreases the number of tags required substantially (a further decrease of 36% in
YRI, 47% in CEU and 55% in CHB+JPT), and yet relative power remains nearly
complete at 96%. Moreover, this approach can straightforwardly be combined with the
multi-marker method described above, resulting in even greater efficiency (Figure 3a).
While even lower r2 thresholds result in less and less genotyping, relative power begins
to decline rapidly. In fact, we find that lowering the r2 threshold too far (while still
requiring that all sites be captured at or above this threshold) can result in performance no
better than random collection of SNPs (Figure 3a).
An alternative approach is to rank order potential tags based on the number of other SNPs
for which they proxy, and then type the SNPs in this priority order (we term this method
"best N"). This approach is significantly more efficient than lowering the r2 threshold: for
example, choosing a SNP every 10 kb in this manner (only -5% of all common SNPs)
provides relative power of 77% (YRI), 95% (CEU) and 92% (CHB+JPT). Of course, any
such pairwise list can be made more efficient by replacing single-marker tests with
appropriate multi-marker haplotypes (as above), resulting in the most efficient method of
those we examined (Figure 3a).
In summary, if a complete reference panel is available, multi-marker haplotype tests are
more efficient than pairwise tests, and prioritizing SNPs based on their LD properties
allows impressive reductions in the genotyping burden while maintaining excellent
power.
Tags selected from an incomplete reference panel
At present, only incomplete reference panels are available genome-wide8' 9. It is therefore
important to ask how power and efficiency decline when tags are selected from an
incomplete, rather than complete, reference panel. To this end, we created a "pseudo" 5
kb HapMap by thinning the ENCODE data to achieve the spacing and frequency
distribution of Phase I HapMap8. We selected tags and designed tests using this
incomplete resource, evaluating performance in simulated case-control panels where all
alleles (not just those from the incomplete HapMap) were allowed to be causal.
We observe two major changes, both unsurprising. First, a much smaller set of tags is
selected for genotyping as compared to when tags are picked using the complete data
(Figure 3b). Second, a subset of common variants have no good proxies in the reference
panel: 55% (YRI), 26% (CEU) and 28% (CHB+JPT) of all common SNPs are not
captured at r2 0.8, because they are not observed in the pseudo HapMap, nor are they in
LD with any other SNP that happened to be includeds .
Given these characteristics, it is noteworthy that power is largely undiminished relative to
testing tags chosen from a reference panel of all common sites: tags selected from the
pseudo Phase I HapMap (pairwise r2 Ž 0.8) provide 91% relative power in CEU (73% in
YRI; 89% in CHB+JPT), despite requiring less than half as many tags compared to
tagging from complete data. In absolute terms, while a set of "best N" tags every 10 kb
(on average) selected from complete data provides 95% relative power in CEU (77% in
YRI; 92% in CHB+JPT), the same density of tags selected from the pseudo Phase I
HapMap retains 88% power in CEU (64% in YRI; 85% in CHB+JPT).
We also asked whether the power provided by different tagging strategies was similar
when performed on incomplete as compared to complete reference panels. Interestingly,
whereas "best N" clearly outperformed lowering the r2 threshold in complete data, this is
no longer the case for tagging from the pseudo HapMap (Figure 3b). Here, the two
methods perform similarly, with an apparent slight edge to lowering the r2 threshold.
The impact of LD on tag SNP selection and power
We were initially surprised by the relatively high power obtained when tags were
selected from incomplete reference panels or when the "best N" method was used to trim
a complete tag set, as in both cases these tags fail to capture a substantial proportion of
putative causal alleles. This behavior is illuminated, however, by the highly variable
extent of LD in the human genome, and the impact of LD on the power obtained from
each statistical test.
The completeness of the reference panel - and the strategy for tagging and testing -
affects not only the distribution of the test statistic for causal SNPs, but also the
significance thresholds under the null. Figure 4a displays the distribution of the
maximum X2 test statistic under two scenarios: tags selected from complete and from
incomplete reference panels. When tags are selected from incomplete data, as expected
the causal distribution is shifted towards lower X2 values, since some causal SNPs are not
well captured. But in addition, the null distribution shifts to lower thresholds due to a
marked reduction in the number of tests performed. That is, although some alleles are
poorly captured and not discovered - most notably those alleles with few proxies
(Supplementary Fig. 2), the power for the majority of putative causal alleles remains high
due to (a) inclusion of a good proxy for most causal alleles, and (b) a less stringent
significance threshold for declaring association. While overall power is similar in both
scenarios (Figure 4b), the mix of causal alleles discovered shifts toward those in LD with
many other SNPs, at the cost of discoveries due to SNPs with few proxies.
Put another way, tests that capture many putative causal alleles add the same amount to
the multiple testing burden as do independent tests that capture only a single site. The
chance of encountering a true association, however, is much greater when many putative
causal alleles are examined per test. While the first tag from the incomplete reference
panel captures only a small fraction of all sites, it does so at the cost of only a single
hypothesis test, and results in relative power that is 15-25% of that obtained by testing all
common sites in the region (data not shown). Of course, adding more tags captures an
ever larger fraction of putative causal alleles, and power rises. But the yield of each
additional test falls monotonically as it examines a smaller slice of the prior distribution
than the test before it.
This simple idea underlies the "best N" method for tag SNP selection, as it preferentially
excludes those SNPs that have no proxies, and which offer the least marginal power per
hypothesis test. Similarly, an incomplete reference panel (HapMap) has also
preferentially (but imperfectly) dropped SNPs with no proxies - such SNPs can only be
tested for association if they are included on the HapMap, while SNPs with many proxies
will almost always be tested as only one of its proxies needs to be present on HapMap.
The "best N" approach fails at sparser densities (in complete and incomplete data, Figure
3), however, because the set of SNPs with no proxies has been depleted, and thus the tags
being dropped carry with them information about an increasingly larger number of
putative causal alleles. The "best N" method suffers further when run on incomplete
reference panels, because from such data it is not possible to distinguish which SNPs
truly have no proxies, and which actually have proxies that have not yet been typed.
Empirically, about 50% of the SNPs on the pseudo HapMap have no observed proxies (at
r2 = 1), and thus are preferentially dropped using "best N". Of these, a large number
actually do have proxies in the complete data, but it is impossible to tell which are which
without more complete data. Thus, where complete data is available (as in selected
candidate genes33), and as denser versions of HapMap become available (such as the
pending Phase II), the impact of the "best N"' method should become more significant,
particularly for choosing marker densities of more than 1 SNP per 10 kb.
Exhaustive haplotype tests to detect less common alleles
Above we considered only scenarios in which the causal alleles are common. Of course,
less common SNPs also influence disease, and might be discovered incidentally even if
tags are selecting and tests designed only to capture common variation. We thus
examined power under the scenario that the causal allele is < 5% in frequency with the
same 95% nominal power (and thus a larger magnitude of effect). Interestingly, while
power for < 5% alleles is reduced compared to that enjoyed for common alleles, it
remains substantial: relative power of 29% (YRI), 23% (CEU) and 15% (CHB+JPT).
Exhaustive haplotype testing has been suggested as an approach to capture alleles not
observed in the reference panel. This approach tests many or all local haplotypes in the
hope that one or more might correspond to an unobserved causal allele 25. The chance of
capturing an unobserved allele is likely to be increased with exhaustive haplotype testing,
because a better proxy for the putative causal allele is obtained. However, this benefit
comes at the cost of numerous additional statistical tests, many of which do not
correspond to any actual variant.
We first evaluated the scenario where exhaustive haplotype testing is performed on tags
picked to capture all common alleles in the complete reference panel (r2 = 1.0), but where
the universe of causal alleles was limited to those with < 5% frequency. As described
previously25, exhaustive haplotype testing increases relative power: 59% (YRI), 58%
(CEU) and 45% (CHB+JPT) (Figure 5a). That is, for less common alleles, the benefit of
finding a better proxy outweighs the cost of multiple comparisons, and results in
substantial power even as compared to testing the less common alleles directly.
In contrast, when the causal alleles were common (> 5%), relative power is reduced by
exhaustive haplotype testing to -85% (Figure 5a). This penalty is not surprising: the
testing burden is increased with no possibility of true benefit, since all putative causal
alleles are already captured.
It seemed more likely that exhaustive haplotype tests might improve power for tags
selected from incomplete data, or at random. When we selected tags from the incomplete
(pseudo Phase I HapMap) reference panel, or at random at lower densities (one common
SNP per 10 kb and 30 kb), exhaustive haplotype tests continued to boost power for less
common alleles, but failed to improve power for common alleles (Figure 5b,
Supplementary Fig. 3). We conclude that in empirical genotype data the benefit of
exhaustive haplotype tests is very real, but primarily limited to lower frequency alleles.
Software
The optimal tradeoff between power and efficiency depends on the resources available
and assumed characteristics of allele frequency and LD for putative causal alleles. Since
investigators will want to make their own decisions, we have implemented these methods
in the web server Tagger (http://www.broad.mit.edu/mpg~tagger/), and the program
Haploview 34 (http://www.broad.mit.edu/mpg/haploview/). The software enables
investigators (a) to select tags from empirical data, using single-marker or specified
multi-marker tests, (b) to rank-order the tags based on proxy count, (c) to record the
statistical tests to be performed on these tags (single-marker tests, specified multi-marker
tests, or exhaustive tests). Haploview can perform association tests based on these
selections, including permutation testing. The software also makes it possible (d) to force
in or exclude specific sets of SNPs as tags based on other considerations, such as the
existence of previous data or a working assay; (e) to incorporate genotyping platform
design scores to pick tags based on the likelihood of success; (f) to evaluate the coverage
with respect to a reference panel (based on r2) for an existing set of user-specified tags;
and (g) to derive specified multi-marker tests from a static list of tags to extend coverage
with respect to a reference panel (such as HapMap).
Discussion
In summary, our analyses indicate that (a) specified multi-marker tests substantially
increase tagging efficiency as compared to single-marker approaches, without loss of
power; (b) when selecting SNPs from very dense reference panels, a method such as
"best N" which rank orders SNPs based on their number of proxies allows dramatic
reductions in genotyping with limited loss of power-substantially outperforming a
method based on relaxing r2 thresholds; (c) sparser sets of tags selected from a pseudo
Phase I HapMap are nearly as powerful as equally sized sets chosen from complete
reference panels; and (d) exhaustive multi-marker tests improve power for less common
causal alleles, but are neutral or reduce power when the causal SNP is common. These
relationships hold for each of the different population samples studied by HapMap,
although the number and performance of tags varies as expected based on the general
extent of LD in each sample.
It has become common practice to select tags until a high threshold for the correlation
coefficient (often r2 2 0.8) is exceeded for all observed sites 14. The use of multi-marker
tests and prioritization of tags permits cost to be substantially reduced, with little loss of
power. Whether it is attractive to take advantage of this tradeoff of efficiency for power
will be different for each investigator, depending on available resources for genotyping,
the sample size and power of the patient sample, the perceived cost of a false negative
study, and the anticipated value of a true positive result.
Whether exhaustive haplotype testing is justified depends on assumptions about the
relative balance of rare and common causal variants, and the completeness of the
reference panel from which tags are picked. Given the current Phase I HapMap, there
appears little cost and evident gain to employing the exhaustive haplotype test 25. As
reference panels become more complete (particularly for less common alleles), however,
the balance may shift towards the specified haplotype-based method that limits tests to
only those that predict the increasingly complete inventory of putative causal sites.
A limitation of our study is that we do not evaluate whether tags and tests defined in the
HapMap samples are transferable across populations, and how this varies for single-
marker and haplotype-based methods. In preliminary analysis we observe minimal loss of
power when tags and tests are transferred to a variety of disease studies (PIWdB, Noel
Burtt, Rob Graham, MJD, DA, manuscript in preparation), and similar findings have
been reported elsewhere '3536 . Much more work is needed on this topic, and the answer
will likely vary depending on the population studied.
In our minds, the most significant observation in this study is that SNPs that capture
many putative causal alleles have different statistical properties than tests capturing only
a single site - at least, under the frequentist approach to setting statistical thresholds. An
implication is that rather than using a universal significance threshold for all tests, power
may be increased by a Bayesian approach in which a prior for each test is established as a
function of the number of sites captured, integrated over each site's individual likelihood
of being causal. Incorporating such ideas into study design may lead to greater efficiency
in use of genotyping resources, and maximize the yield of discoveries for a given
investment in such research.
Methods and Materials
Data sets
We used phased genotype data for ten chromosomal regions, each spanning 500 kb,
generated as part of the HapMap-ENCODE project
(http://www.hapmap.org/downloads/encodel.html.en). This data set (release 16c.l) is
based on genotyping all variable sites observed after resequencing 48 unrelated
individuals (as well as any additional SNPs in dbSNP) in the 269 DNA samples used in
HapMap: 30 parent-offspring trios from the Yoruba people of Ibadan, Nigeria (YRI); 30
parent-offspring trios from Utah residents with northern and western European descent
(from the Centre d'Etude du Polymorphisme Humain; CEU); 45 unrelated Han Chinese
from Beijing, China (CHB); and 44 unrelated Japanese from Tokyo, Japan (JPT). We
have combined the CHB and JPT samples for all analyses performed, yielding three
analysis panels: YRI, CEU (both 120 unrelated chromosomes) and CHB+JPT (178
chromosomes).
Genetic model and simulation of case-control panels
From the ENCODE data, we generated almost 10 million case-control panels to evaluate
study-wide power as a function of a number of tagging/testing strategies. A
multiplicative disease model was employed in which we nominate all non-singleton
SNPs in the complete data to be causal, one by one, reflecting a uniform prior probability
of any of the SNPs contributing to the phenotype. For each causal SNP, 250 replicate
case-control panels were made by sampling with replacement from the ENCODE
chromosomes to give 1,000 cases and 1,000 controls (4,000 chromosomes in total). The
frequency of the causal allele (minor/major chosen at random) in the cases is determined
by the genotype relative risk, calibrated so that we obtain 95% nominal power to detect
an association with the 1 d.f. chi-square test (at P < 0.01), if that causal SNP was tested
directly (Supplementary Fig. 1). Thus, all causal SNPs are assigned to have equal
nominal power. We also created control-control (null) panels by randomly sampling from
the ENCODE chromosomes; these were used to define statistical significance thresholds.
Reference panels for tag SNP selection
Reference panels were constructed at two densities: (1) "complete" reference panels
based on all ENCODE data (120 unique chromosomes for YRI and CEU; 178 for
CHB+JPT), where complete refers to the ascertainment of common (>5%) variation; and
(2) "incomplete" reference panels by thinning the data as follows. To mimic the
ascertainment scheme of the 5 kb HapMap (Phase I), we randomly picked SNPs present
in dbSNP build 121 (excluding "non-rs" SNPs in HapMap release 16a) for every 5 kb bin
until a common (MAF 2 5%) SNP was picked (allowing up to three attempts per bin).
Selection of tag SNPs and definition of tests
We have developed a computer program called Tagger for selecting tag SNPs and
defining tests from a reference panel. Tags can be picked in different ways: (1) greedy
pairwise tagging 14, in which alleles of interest are captured by single-marker tests at the
prescribed r ; (2) prioritizing tags ("best N") by the number of alleles they can proxy for
at a given r2. In addition, Tagger can perform an aggressive search to attempt to replace
each tag with a specific multi-marker predictor (on the basis of the remaining tags) to
improve efficiency. This predictor will be accepted only if it can capture the alleles
originally captured by that discarded tag at the required r2; otherwise, that tag is
considered indispensable. As a result of this "peel back" approach, we end up with fewer
tags that specify a similar (identical if r2 = 1) set of 1 d.f. statistical tests as the original
set of single-marker tests. In this study, we allow up to three tags to form a specified
multi-marker test, and limit the search to evaluate at most 10,000 allelic predictors. The
maximum allowed physical distance between an allele and a tag was 200 kb. To
minimize risk of overfitting, tags within a specified multi-marker test are forced to be in
strong LD (here defined as the LOD score on ID'I > 3) with one another and with the
predicted allele.
Region-wide test statistic and power calculations
For every explored tagging/testing scenario, we generate a set of 1 d.f. chi-square allelic
tests. Our region-wide test statistic for association is the maximum of these chi-square
values. The null distribution of the test statistic was generated by performing the same
allelic tests in the random null panels, and used to derive the significance threshold
corresponding to a region-wide P = 0.01 (see Supplementary Note for a brief discussion
on how this compares to explicit permutation testing). The absolute power to detect
association is computed as the fraction of the case-control panels in which the maximal
chi-square test statistic exceeds the significance threshold (when a true association is
declared). To normalize results for different strategies, we: report power (for both
common and rare causal alleles) relative to the power to detect common causal alleles
(MAF 2 5%) when these are tested directly, averaged over all 10 ENCODE regions.
Exhaustive haplotype tests
Exhaustive haplotype tests were performed by enumerating all haplotypes corresponding
to adjacent combinations of tags of all sliding windows of a maximum span. We applied
this to pairwise tags (selected at r2 = 1 from complete panel) forming haplotypes of up to
25 kb, and 17 and 50 random common markers per region (30kb and 10 kb average
spacing, respectively) from incomplete reference panels forming haplotypes of up to 100
..,kb. Allelic chi-square tests were performed on these haplotypes, as above.
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Figure 1: Distributions of the test statistic in a typical ENCODE region. Maximum chi-square statistics
for association to disease status are evaluated in the simulated case-control panels (solid line) and random
null panels (dotted line). The study-wide significance threshold (vertical grey line) is empirically
determined such that the maximum chi-square test statistic exceeds it in 1% of the null panels (region-wide
P = 0.01). True associations in the simulated case-control panels with a test statistic below the threshold
are rejected (false negatives). Due to the empirical multiple testing correction, absolute power to detect an
association drops from 95% (nominal) to 60% (YRI) and 68% (CEU and CHB+JPT), averaged over all 10
ENCODE regions.
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Figure 2: Efficiency afforded by a tagging approach. Using a pairwise tagging and single-marker
analysis strategy, a non-redundant (r = 1) subset of all SNPs provides 100% relative power to capture all
common SNPs (2 5%) in the ENCODE data. Efficiency is increased further, while retaining 100% ielative
power, by the use of multi-marker haplotypes as described in the text.
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Figure 3: Efficiency and power for various tagging strategies. Relative powdr to detect associations due
to common (> 5%) causal alleles is shown as a function of the average spacing of tags for multi-marker
tagging from (a) complete reference panels and (b) incomplete reference panels (pseudo Phase I HapMap).
Tags are picked by random selection of common SNPs (dotted line); by lowering the r2 threshold (dashed
line); and by prioritizing "best N" tags according to number of proxies (solid line). In the top panel,
expected power is displayed for a hypothetical scenario in which there is no LD among SNPs, and all tests
are independent (grey dotted line); the comparison of this line to the actual data shows the tremendous gain
in efficiency and power offered by the extensive LD in the human genome.
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Figure 4: Effect of tagging from an incomplete reference panel on the testing burden and power. (a)
Null (dotted lines) and causal (solid lines) distributions of the test statistic are plotted for two scenarios:
tagging from complete (in blue) and incomplete (in red) reference panels. The causal distribution as well as
the region-wide significance threshold are reduced concomitantly when tags are picked from the pseudo
Phase I HapMap, thus preserving power. (b) Distribution of region-wide power for individual causal alleles
is plotted for two scenarios: tagging from complete (in blue) and incomplete (in red) reference panels.
Nominal power is centered around 95% (dotted grey line). Overall power is comparable in both scenarios,
for reasons discussed in the text.
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Figure 5: Effect of exhaustive haplotype tests on statistical power. Relative power is given for common
(2 5%) and less common (< 5%) causal alleles for two scenarios: (a) when a non-redundant set of SNPs are
used as tags from complete reference panels; and (b) when tag SNPs (MAF > 5%) are randomly selected
every 10 kb from pseudo Phase I HapMap (as in Ref. 25). Power is computed when each tag SNP is tested
for association using single-marker tests (-), and when exhaustive haplotype tests are performed on the
same data (+). Exhaustive haplotype tests increase power for less common alleles, but at a cost of reduced
power for common alleles.
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Supplementary Figure 1: Genotype relative risk as a function of the frequency of the causal variant.
Less common alleles are assigned a greater effect size than common alleles to achieve constant nominal
power of 95%.
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Introduction
The International HapMap Project provides empirical genotype data for >4
million SNPs in a limited sample of 270 individuals from four populations"' 2. There are
two fundamental questions with regard to a dense reference panel such as HapMap. First,
to what extent is power compromised when tags are selected from incomplete genotype
data in the reference panel? Second, how is power affected when tags are selected from a
reference panel but then genotyped in another population sample? We addressed the first
question in previous work, where we investigated the quantitative relationship between
marker density and power in simulated association studies using HapMap ENCODE
data3 . Here, we characterize the extent to which tag SNPs picked from HapMap DNA
samples are transferable across different population samples.
Results
To this end, we have collected dense genotype data uniformly across HapMap and
non-HapMap population samples. As part of the Multiethnic Cohort (MEC) study4'5, we
first compiled a list of genes in the steroid hormone and growth factor pathways for a
comprehensive study of genetic variation. We selected a dense set of SNPs from the
public dbSNP database6, augmented by SNP discovery through exon resequencing in
each of these genes in 190 cases with breast and prostate cancer from five different ethnic
groups (Supplementary Table 1). In total, we attempted genotyping for 3,302 SNPs in
over one thousand DNA samples from 15 different population samples (Table 1 and
Supplementary Table 2). Keeping all SNPs that were successfully genotyped in all
population samples and polymorphic in at least one (Supplementary Table 3), the final
data set contained 1,679 SNPs across 25 genes with a total span of 2.6 Mb
(Supplementary Table 4). With an average marker density of 1 SNP per 1.6 kb
(approaching that of Phase II HapMap), this data set provides good coverage of common
variation, consistent with previous evaluations2' 3.
To assess the transferability of tags picked from HapMap samples for association
studies in other population samples, two relevant measures are (a) the distribution of the
correlation (r2) between the allelic tests (based on the tags) and the collection of all
"untyped" variants (that is, SNPs not selected as tags) present in these samples, and (b)
how this translates into study-wide power to detect an association under a specified
disease model. We prefer these measures to comparisons based on differences in LD
structure7-9, haplotype diversity'0 or allele frequencies I1 , as the question of immediate
interest is the impact of any such differences on the power in the disease study.
Using only the genotype data collected in each HapMap panel (YRI, CEU, CHB
and JPT), we selected tags until every SNP observed with Ž5% allele frequency in that
panel was captured with a pairwise r2 > 0.8 by at least one tag. By definition, these tags
capture the "untyped" common SNPs (>5%) at a maximum r2 > 0.8 in that HapMap
panel. Using this strategy, the mean maximum r2 between the tags and the "untyped"
SNPs was 0.93-0.96, and many "untyped" SNPs had a perfect proxy (maximum r2 = 1)
(Figs. la-d). The number of selected tags tracked inversely with the extent of LD in these
samples.
Before considering transferability across population samples, it is crucial to
measure the effect of transferability to a second, independent sample from the same
population. Specifically, we expect to see statistical fluctuation in allele frequencies
around the 5% threshold for tag SNP selection. For example, SNPs with an estimated
allele frequency just below the 5% threshold will not be targeted during tag SNP
selection (and may not be captured), but may well have an allele frequency above this
threshold in a second sample. Conversely, SNPs with an estimated allele frequency just
above the 5% threshold will be captured by a tag but may fall below the threshold in a
second sample, and may therefore not be included in the assessment. Furthermore, there
is fluctuation in the estimated r2 for pairs of SNPs in independent samples of limited size:
SNPs captured with r2 > 0.8 by a tag in one sample may be captured with r2 < 0.8 in a
second sample (and vice versa) due to random fluctuations in the chromosomes chosen
for each sample. These effects are a natural consequence of sampling variability and
employing strict allele frequency and r2 thresholds.
We characterized the extent of sampling variation in the HapMap reference panels
by evaluating the coverage of common SNPs in independent samples drawn from the
same population. The vast majority of the "untyped" common SNPs were still captured
with a maximum r2 > 0.8: 74% in HGDP-YRI, 89% in CEPH-EXT, 82% in HGDP-CHB
and 79% in HGDP-JPT (Figs. le-h and Table 2). Moreover, nearly all SNPs were
captured with a maximum r2 > 0.5. The observed loss is interpreted as statistical
fluctuation caused solely by drawing independent samples of limited size from the same
underlying population, resulting in modest r2 overestimation.
A small fraction of "untyped" SNPs, however, are not well captured: between 1
and 6% of "untyped" SNPs had a maximum r2 < 0.5 in the second, independent sample
from the same population (Figs. le-h). Upon closer inspection, these poorly captured
SNPs typically had a lower allele frequency. All SNPs with a maximum r2 < 0.5 in
CEPH-EXT had a frequency below 5% in the HapMap CEU panel (a few were
monomorphic), and were consequently missed, as no tags were explicitly picked to
capture them (Fig. 2). This minor loss is due to the fluctuations in the allele frequency
estimates, and not due to differences in LD structure. In contrast, only half of the SNPs
with a maximum r2 < 0.5 in HGDP-YRI are due to this allele frequency effect, with the
other half showing a substantial drop in r2 even though these SNPs were present at >5%
in both samples. This was primarily limited to regions with low LD.
Having assessed the transferability within samples of the same population, we
next examined transferability to samples with similar continental ancestry as the CEU
and JPT HapMap panels, but sampled from different populations. Using the tags picked
from HapMap CEU samples, we evaluated the coverage of common variants in self-
described "White" individuals from Hawaii (MEC-W) and in individuals from the Botnia
region of Finland (BOT). The performance of the tags was essentially unchanged, when
compared with independent samples from the same underlying population as the HapMap
panels (Fig. li-j). The mean maximum r2 of "untyped" SNPs was 0.88-0.90 (Table 2). In
both samples, only 3% of "untyped" variants were captured with a maximum r2 < 0.5.
We also evaluated the coverage in Japanese samples from Hawaii and Los Angeles,
California (MEC-J) for tags picked from HapMap JPT samples. Performance was similar:
87% of "untyped" variants were captured with a maximum r2 > 0.8 with a mean
maximum r2 of 0.91 (Table 2), and only 1% captured with a maximum r2 < 0.5. Thus,
there is very little additional loss in coverage beyond that observed previously within
independent samples from the same population.
We next evaluated the performance of tags picked from the YRI HapMap samples
in African-American samples from Los Angeles, California (MEC-AA), and from
Chicago, Illinois (MAY). Of all "untyped" common variants, 62% were captured with a
maximum r2 0.8 with a mean maximum r of 0.80-0.81 (Table 2). A comparatively
larger (though still modest) fraction of SNPs (8-10%) was poorly captured with a
maximum r2 < 0.5 (Fig. lb). This is not surprising: although African-Americans are
estimated to have on average 80-85% African ancestry 12, a tagging strategy that takes
into account the combined African and European ancestry of these samples would be
expected to provide better coverage, as we indeed demonstrate below.
While these results are encouraging, we wanted to obtain a more direct estimate
of statistical power in a disease study. Because of the correlated nature of dense SNP data
and the number of statistical tests, it is not straightforward to estimate power directly
from the r2 distribution. Thus, we simulated case-control association studies for each non-
HapMap population sample following a recently described procedure3 . In these
simulations, we nominated each common SNP with >5% allele frequency in that non-
HapMap sample in turn to be "causal" (with modest effect) and generated a large number
of simulated case-control panels. We evaluated power by performing the association tests
(based on the tags selected from the HapMap samples) in these case-control panels and
counting the number of panels in which we were able to detect an association at a gene-
wide corrected P value of 0.01, averaged over all 25 genes. We report both the power to
detect all common causal alleles (tags and "untyped" SNPs), and the power to detect only
"untyped" common variants (that is, SNPs not selected as tags). We express power
relative to that obtained by testing all common SNPs observed in the non-HapMap
sample for association (as if we had genotyped directly all common SNPs in the case-
control samples).
In independent samples from the same populations as the HapMap samples,
power was 95-97% relative to the power obtained by testing all common SNPs in those
samples, with slightly less power for the "untyped" common SNPs (Table 3). Power was
essentially unchanged in MEC-W and BOT (using CEU tags) and in MEC-J (using JPT
tags). Performance was somewhat lower in the African-American MEC-AA and MAY
samples: relative power was 92% for tags picked in YRI. (For the sake of comparison, if
we picked tags in CEU alone, relative power dropped to 79%.)
We attempted to improve the power for the African-American samples by picking
tags from all four HapMap population samples combined (rather than picking tags from
the YRI panel only). At an additional genotyping cost (22% more tags), this
"cosmopolitan" tagging approach increased the relative power to 96% in both African-
American samples with 89-90% relative power for the "untyped" common variation
(Table 3). This result demonstrates that tags from the HapMap populations are able to
provide good power in these samples. It is likely that tag SNP selection could be made
more efficient by incorporating knowledge about the underlying local ancestry. Power in
both African-American samples did not deteriorate when tags were picked from HapMap
YRI and CEU panels (and not CHB and JPT), with a modest decrease in the number of
tags. This is not unexpected: tags from CHB and JPT that are not redundant with tags
from YRI and CEU include mostly SNPs that are unique to these two East-Asian
populations.
For some population samples like Native Hawaiians (MEC-H) and Latinos
(MEC-L) from the MEC, there is no obvious choice of HapMap reference panel from
which to pick tags. Nevertheless, when we used CEU in our initial attempt, relative
power was 94% (89% for "untyped" variants) in MEC-H, and power in MEC-L was only
slightly worse (Table 3). The cosmopolitan tags improved relative power to 97-99% in
both population samples, albeit at a greater genotyping cost.
Recently, we introduced specified multimarker (haplotype) tests as a means to
improve upon pairwise tagging in terms of genotyping efficiency without sacrificing
power3. In this approach, specific haplotypes act as effective surrogates for single tag
SNPs. This keeps the multiple testing burden constant while decreasing the number of
tags (but requiring greater genotyping quality and performance). When we used this
"aggressive" tagging approach to capture all common SNPs with r2 > 0.8, the genotyping
burden was reduced by 15-23% compared with pairwise tagging. Power in simulated
association studies in non-HapMap population samples remained essentially unchanged
with this more efficient tagging approach. Hence, this multimarker tagging strategy is
robust to transferability at least for the DNA samples tested here. An important
implication of this result is that specified multimarker tests inferred from a dense
reference panel (such as HapMap) can act as effective predictors for (some) untyped
SNPs. We have recently demonstrated that this approach can provide a significant boost
in the coverage of commercially available whole-genome products 3.
Discussion
Our work is broadly consistent with other assessments of tag transferability14"24
To our knowledge, this is the first systematic study to assess tag transferability using
dense genotype data in all four HapMap population samples and many other samples. We
estimated the effect of transferability on study-wide power and coverage of common
variation, and we find that it is almost completely maintained in the non-HapMap
samples. The minor loss in power that is observed is due largely to fluctuations around
the allele frequency threshold (say, 5%) during tag SNP selection rather than true
differences in LD between SNPs. These results indicate that tags selected from the
HapMap samples can provide good power to study the role of common polymorphisms in
complex traits in samples from many regions throughout the world.
Methods and Materials
DNA samples
We collected genotype data in the following DNA samples: 30 parent-offspring trios
from the Yoruba people in Ibadan, Nigeria (YRI), 27 parent-offspring trios from Utah,
USA, with northern and western European ancestry (from the Centre d'Etude du
Polymorphisme Humain; CEU), 45 unrelated Han Chinese people from Beijing, China
(CHB) and 44 unrelated Japanese people from Tokyo, Japan (JPT), also used in the
International HapMap Project2; 25 unrelated individuals from Ibadan, Nigeria (HGDP-
YRI), 40 unrelated Han Chinese from Beijing, China (HGDP-CHB), 31 unrelated
Japanese from Tokyo, Japan (HGDP-JPT) from the Human Genome Diversity
Project25,26; 62 trios from Utah, USA, with northern and western European ancestry from
the CEPH collection (CEPH-EXT); 70 self-described African-American (MEC-AA), 69
self-described Native Hawaiian (MEC-H), 70 self-described Japanese (MEC-J), 70 self-
described Latino (MEC-L) and 70 self-described White (MEC-W) samples from the
Multiethnic Cohort study conducted in Hawaii and California (mainly Los Angeles),
USA; 30 trios from Botnia, Finland (BOT); and 48 unrelated African-Americans from
Chicago, Illinois, USA (MAY). These studies were approved by the Human Subject
Institutional Review Boards at the respective institutions, and informed consent was
obtained from all subjects.
SNP discovery
We performed exon resequencing in 95 cases of advanced breast cancer and 95 cases of
advanced prostate cancer from the Multiethnic Cohort study. These are 19 samples from
each of the five populations represented in the Multiethnic Cohort (see above) that do not
overlap with the samples used to collect genotype data). Summary statistics are given in
Supplementary Table 1.
SNP genotyping
A dense set of SNPs was selected for genotyping from two sources: (1) SNPs discovered
by resequencing that were not in dbSNP (version 117) and that were located in exons or
UTRs, and subsequently (2) SNPs from dbSNP (version 119) and Celera databases
prioritizing "double-hit" and missense SNPs. Genotyping was performed to generate an
initial map of roughly evenly spaced SNPs in the African-American MEC samples to
classify regions according to their degree of LD, and to provide a guide for further
genotyping. SNP density was preferentially increased in regions of low(er) LD as
inferred from the initial map. In total, we attempted 3,302 SNP assays in 1,029 samples
using the Sequenom MassArray and Illumina GoldenGate platforms (Supplementary
Table 2). Concordance between the Sequenom and Illumina platforms was 98.2%
(12,927 out of 13,170) for 863 markers typed in 16 identical samples. In the 15
population samples, on average, 84% (2,774) of the attempted assays passed quality
control filters, defined as genotyping completeness >90%, no more than 1 concordance
error, no more than 1 Mendel inheritance error, and P > 0.001 for the Hardy-Weinberg
test (Supplementary Table 3). This resulted in a working set of 1,842 SNPs that passed
QC in all 15 population samples, including 1,679 SNPs that are polymorphic in at least 1
population sample (1,473 SNPs with >5% frequency) (Supplementary Table 4). All
genotype data were phased using the program PHASE 2.1.1 (ref. 27) to produce phased
chromosomes that were used in all analyses. For the purposes of estimating (high) r2
values between SNPs, the impact of potential phasing errors is expected to be minimal28
Simulation of case-control association studies
We simulated case-control panels for every gene to evaluate study-wide power. We used
a multiplicative genetic model in which we designated all common SNPs, one by one, to
be "causal". For each causal SNP, we made case-control panels by sampling with
replacement chromosomes from the phased data to give 1,000 cases and 1,000 controls
(4,000 chromosomes in total). As a function of the allele frequency of the designated
"causal" allele, we set the genotype relative risk to obtain a constant 95% power at a
nominal P of 0.01 using a 2 x 2 chi-square test. We generated 75 replicate case-control
panels per causal SNP, and all SNPs have an equal chance of being causal. We also
generated 75,000 control-control (null) panels by sampling chromosomes at random from
the phased data. These null panels have no causal SNP and were used to derive gene-
wide significance thresholds (see below).
Tag SNP selection
We used the program Tagger to derive a set of tag SNPs from the HapMap reference
panel such that each allele that satisfies the allele frequency threshold is captured at the
given r2 threshold either by a single tag (pairwise tapging) 9, or by a specified
multimarker (haplotype) test ("aggressive" tagging) . We noticed that the efficiency gain
afforded by aggressive tagging was less than that observed in previous analyses of the
HapMap-ENCODE data2' 3; this can be explained by the fact that this study focuses on
gene regions of-100 kb size (compared to 500 kb ENCODE regions)30 . We introduce a
"cosmopolitan" tagging approach for picking tag SNPs that are maximally informative in
multiple reference panels simultaneously. To this end, we implemented a greedy
algorithm that maximizes, for every additional tag, the total number of alleles captured
with the user-defined r2 threshold, observed in the HapMap panels under consideration.
This is similar in spirit to another approach that was recently described3 1.
Power calculations
We evaluated power by performing the allelic tests (based on the selected tags) in the
simulated null panels and the case-control panels. We derived significance thresholds
from the null panels that correspond to a gene-wide corrected P of 0.01. We counted the
fraction of case-control panels in which we observed a test statistic greater than the
significance threshold. We report the average power, relative to that obtained by testing
all common SNPs in that non-HapMap sample directly. Testing all common SNPs in the
simulated case-control panels resulted in an absolute power of 82% in HGDP-YRI, 84%
in CEPH-EXT and HGDP-CHB, and 85% in HGDP-JPT. This is substantially higher
than the corresponding power in HapMap ENCODE data under the identical genetic
model (60% in YRI and 68% in CEU and CHB+JPT)3. These differences correspond to
a general reduction in the multiple testing burden. This is due to two effects. First, the
genes in the current data set are on average 100 kb in size (much shorter than the 500 kb
ENCODE regions). Second, the ascertainment of the current study was not as complete
as that of the HapMap ENCODE project.
Figures and Tables
Table I -Population samples Included in this study
Samples and origin
SUtah, USA, European ancestry from CEPH (HapMap)
Utah, USA, European ancestry from CEPH
Whites from Hawaii, USA, from Multiethnic Cohort
.Bothia, Finland
Han Chinese from Beijing, Chiria (HapMap)
Han Chinese from Beijing, China, from Human Genome Diversity Project
Japanese from. Tokyo, Japan (HapMap)
Japanese from Tokyo, Japan, from Human Genome Diversity Project
Japanese from Hawaii and Los Angeles, Califomia, USA, from Multiethnic C(
Yoruba from Ibadan, Nigeria (HapMap)
Yoruba from Ibadan, Nigeria, from Human Genome Diversity Project
African-Americans from Los Angeles, California, USA, from Multiethnic Coho
African-Americans from Chicago, Illinois, USA
Native Hawaiians from Hawaii, USA, from Multiethnic Cohort
Latinos from Los Angeles, California, USA, from Multiethnic Cohort
Number of
Abbreviation chromosomes
in final data set
CEU
CEPH-EXT
MEC-W
BOT
CHB
HGDP-CHB
JPT
HGDP-JPT
MEC-J
YRI
HGDP-YRI
MEC-AA
MAY
MEC-H
MEC-L
104
248
136
116
88
80
88
62
136
120
50
138
96
138
138
Table 2 - Coverage of common variation in the non-HapMap population
by tags picked from the HapMap samples. Coverage is expressed as
the mean maximum r2 for all SNPs and "untyped" SNPs with frequency
>5% in the non-HapMap population samples.
Mean maximum Mean maximum r 2Reference panel Population r2 for all common for"untyped"(HapMap samples) sample r for all common for "untyped"SNPs common SNPs
CEU CEPH-EXT 0.95 0.91
CEU MEC-W 0.93 0.88
CEU BOT 0.94 0.90
CHB HGDP-CHB 0.93 0.90
JPT HGDP-JPT 0.93 0.89
JPT MEC-J 0.94 0.91
YRI HGDP-YRI 0.94 0.86
YRI MEC-AA 0.92 0.81
YRI MAY 0.92 0.80
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Figure 1. Performance of tags evaluated in multiple population samples, expressed as the percentages
of common SNPs (excluding the tags) captured with the given maximum r2 (in three bins: 0 < r2 < 0.5, 0.5
< r2 < 0.8; 0.8 < r2 < 1.0). Tags are picked from the HapMap DNA samples so that every SNP with >5%
allele frequency is captured by a tag with pairwise r2 > 0.8. We show performance in each HapMap
sample: (a) YRI, (b) CEU, (c) CHB, (d) JPT; in additional samples from the same populations as the
HapMap samples: (e) HGDP-YRI (using tags from YRI), (f) CEPH-EXT (using tags from CEU), (g)
HGDP-CHB (using tags from CHB), (h) HGDP-JPT (using tags from JPT), respectively; and in other
samples: (i) MEC-AA (using tags from YRI), (j) MAY (using tags from YRI), (k) MEC-W (using tags
from CEU), (1) BOT (using tags from CEU), (m) MEC-J (using tags from JPT). Darker shade is used for
SNPs captured by a perfect proxy (maximum r2 = 1).
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Figure 2. The effect of allele frequency on: the maximum r2 between the tag SNPs (picked from the
HapMap CEU samples such that SNPs >5% are captured with pairwise r2 > 0.8) and the "untyped"
common SNPs in the additional CEPH samples (CEPH-EXT). SNPs that are captured with lower
maximum r2 tend to have a lower allele frequency. Plotted is the linear regression line to fit this
relationship (P < 10-7).
Table 3: Relative power in simulated case-control association studies in
non-HapMap populations. Tags were picked from the reference panel so as to capture all
observed with >5% frequency In that panel with a pairwlse r2 > 0.8.
The relative power is the power to detect causal alleles (SNPs with M5% frequency in the
non-HapMap population sample) in comparison to the observed power when all causal al
are tested directly (I.e. no tagging). Power is given for all common SNPs as well as
the subset of common SNPs that were not picked as tags ("untyped").
Cosmopolitan tagging refers to picking tags to capture common variation in all four
HapMap populations simultaneously.
Reference panel Number of Relative power for Relative power for
(HapMap picked tags Case-control panel all common causal "untyped" common
samples) alleles (%) causal alleles (%)
CEU 470 CEPH-EXT 97 95
CEU 470 MEC-W 96 91
CEU 470 BOT 96 89
CHB 388 HGDP-CHB 96 92
JPT 415 HGDP-JPT 96 92
JPT 415 MEC-J 96 92
YRI 724 HGDP-YRI 95 87
YRI 724 MEC-AA 92 81
YRI 724 MAY 92 81
Cosmopolitan 885 MEC-AA 96 90
Cosmopolitan 885 MAY 96 89
CEU 470 MEC-H 94 89
Cosmopolitan 885 MEC-H 99 96
CEU 470 MEC-L 92 83
Cosmopolitan 885 MEC-L 97 94
Supplementary Table 1: Summary of SNP discovery through resequencing
* Bases
sequenced
1530
2088
1101
1224
2100
764
987
* Bases
passing
QC
1266
1872
833
776
1907
764
767
* SNPs
discovered
25
21
9
7
42
14
7
1869 1869 26
780 426 20
351 351 4
1788 1780 42
7476 7068 100
684 660 20
1281 1078 2
279 279 6
1527 1297 31
390 390 7
2802. 2275 40
462 280 9
1593 1593 19
1566 1566 23
1512 1463 41
1164 951 11
1209 1209 16
36527 32720 542
Number of SNPs identified by resequencing validation rate=
'Number of SNPs already described in dbSNP (build 117) 67.61%
Number- of novel SNPs attempted for validation (successful genotyping assay designed)
Number of novel validated SNPs that passed the QC thresholds described in the methods
" Number of novel missense SNPs validated in the resequencing panel (n= 190)
Number of novel missense SNPs above 1% in the resequencing panel (n190)
7 Number of novel missense SNPs above 1% in the Multi-Ethnic Cohort panel (n=349)
eThe FST gene was not resequenced as part of this study
Supplementary table 2 is 40 pages long and appears only in the online supplement to the original
publication.
Supplementary Table 3: Genotyping summary of the final data set
QC passing SNPs1  Polymorphic SNPs2
Average Average
Locus Chr Position (hg16) Size (kb) Number spavi b) Number pacing b)
ACVR1 2 158784754-158916981 132 84 1.6 75 1.8'
FSHR 2 49157637-49375736 218 141 1.5 131 1.7
INHA 2 220611238-220652419 41 13 3.2 9 4.6
INHBB 2 121171479-121214066 43 13 3.3 11 3.9
LHCGR 2 48878904-48977278 98 116 0.8 108 0.9
SRD5A2 2 31715642-31793965 78 30 2.6 27 2.9
GNRHR 4 68594632-68648684 54 46 1.2 44 1.2
FST 5 52776937-52806789 30 26 1.1 24 1.2
PRLR 5 35084938-35301367 216 183 1.2 166 1.3
SRD5A1 5 6666565-6730425 64 52 1.2 50 . 1.3'
CGA 6 87780870-87819426 39 39 1.0 37 1.0
ESR1 6 152136584-152472230 336 246 1.4 238 1.4
IGF2R 6 160276511-160448209 172 163 1.1 148 1.2
PRL 6 22375954-22438440 62 67 0.9 60 1.0
INHBA 7 41449576-41512218 63 44 1.4 ,42 1.5.
GNRH1 8 25287836-25325323 37 12 3.1 12 3.1
CYP17 10 104234154-104360966 127 50 2.5 41 3.1
FSHB 11 30198703-30228677 30 10 3.0 9 3.3"
PGR 11 100437852-100555849 118 106 1.1 96 1.2
IGF1 12 101244363-101400231 156 93 1.7 75 2.1
ESR2 14 62680052-62769843 90 36 2.5 33 2.7
CYP11AL 15 72335354-72402356 67 21 3.2 18 3.7
CYP19 15 49188301-49381873 194 95 2.0 91 2.1
HSD17B2 16 81813649-81929978 116 137 0.8 118 1.0"
SHBG 17 7711853-7754309 42 19 .2.2 16 2.7.
Overall 2,623 1,842 1.4 1,679 1.6
These SNPs pass QC in all 15 population samples, including monomorphic SNPs
2 These SNPs are QC passing and polymorphic in at least 1 of the population samples
60
* coding
exons
9
10
2
2
11
5
3
# coding
exons
passing
QC
8
10
1
1
10
5
2
* SNPs in
dbSNP'
8
3
2
1
12
4
2
* Novel SNPs
attempted for
vahldaton
3
16
18
7
6
27
10
5
* Novel
missense
SNPs s
0
0
0
1
1
* Novel
validated
SNPs
15
9
1
3
9
8
3
Locus
ACVR1
FSHR
INHA
INHBB
LHCGR
SRDSA2
GNRHR
FST#
PRLR
SRDSAI
CGA
ESR1
IGF2R
PRL
INHBA
GNRH1
CYP17
FSHB
PGR
IGF1
ESR2
CYP11AI
CYP19
HSD1782
SHTot
Total
# Novel
missme SNPs
above 1% (in
resequenong
P1)6
0
0
1
0
0
# Novel
missense SNPs
above 1% (Multi-
Ethnic Cohort
panel)'
0
0
0
0
0
1
0
_
~ ~ ~ ---
Supplementary Table 4: Genotyping summary by population
HapMap samples additional samples as Haplapp Multiethnic Cohort
HGDP- CEPH- HGDP-
YRI CEU CHS JPT YR1 EXT HGDP-CHB JPT MEC-AA MEC-H MEC-3 MEC-L MEC-W MAY BOT
Total SNPs passing QC' 2811 2843 2827 2815 2625 2901 2744 2712 2656 2661 2656 2658 2665 3005 3029
Monomorphic SNP 783 841 1051 1050 724 799 996 1004 530 708 904 615 657 632 972
Polymorphic SNP 2028 2002 1776 1765 1901 2102 1748 1708 2126 1953 1752 2043 2008 2373 2057
Total SNPs Faling QC ' 480 452 475 487 677 372 558 590 646 641 646 644 637 297 273
Gerotypin <90% 469 440 462 475 674 353 555 586 615 615 515 615 615 272 271
HWE P<0.001 11 11 12 11 3 19 3 4 23 19 23 22 14 25 2
> I~ endel error 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
>,I concordarce error 0 1 1 1 0 0 0 0 8 7 8 7 8 0 0
'Total number of SNPs that passed quality cn:troi (QC) parameters deined in methods
'Total number of SNPs that failed qua•ft control (QC) par'ameters defined in methods
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Introduction
Whole genome association studies are a comprehensive approach to testing the
hypothesis that common alleles contribute to heritable phenotype variationl' 3. While
neither resequencing every base nor typing all 11 million currently known polymorphic
sites in the human genome4 is yet technically feasible, a practical path to genomewide
association studies has been opened by the introduction of genomewide SNP arrays 5,6
that type 100,000 to 500,000 SNPs per sample.
Such association studies benefit greatly from linkage disequilibrium 1,2,7, the correlation
between the SNPs on each array and other nearby (untyped) putatively causal alleless .
With the completion of the Phase II of HapMap9, it becomes possible to address two
important questions with respect to the use of these arrays. First, to what extent do the
fixed set of SNPs on these arrays capture the information about common variation in the
human genome? 1' Second, is it possible to devise analytical strategies that make use of
HapMap data to increase the chance to discover a true association?
Results
We evaluate three whole-genome products: the 100K and 500K GeneChip Mapping Sets
of Affymetrix6, and the Sentrix HumanHap300 BeadChip by Illumina 5 (products which
contain 116,204, 504,152 and 317,503 SNPs, respectively). Figures for the GeneChip
500K and HumanHap300 products are based on lists of SNPs included on the product
(rather than established genotyping performance in laboratories around the world), and
thus should be considered preliminary, best-case scenarios. Updated information about
evaluations of these and subsequent products are and will be available online.
SNPs included on the Affymetrix products have been pre-selected primarily on the basis
of technical quality and thus represent a quasi-random set of SNPs. In contrast, SNPs on
the Illumina product were selected using a pairwise-correlation-based algorithm applied
to genotype data of HapMap Phase I SNPs in the CEU panel (CEPH-collected samples of
Utah residents with European ancestry)".
Evaluation of each marker set would ideally involve measuring the extent to which they
are correlated to every putative causal common allele along the genome. While complete
polymorphism data does not yet exist to support such an analysis, all three array SNP sets
have been typed in the HapMap reference samples of 270 individuals from four
population samples9. These panels therefore allow, in principle, evaluation of correlation
in two datasets: the ENCODE data of 10 regions spanning 5Mb, with essentially
complete ascertainment for alleles with frequency >5% 12,13, and the genomewide Phase
II HapMap, which includes roughly 3.9 million SNPs successfully typed to date. We
therefore evaluate the GeneChip 100K and 500K arrays vis-A-vis ENCODE, while
evaluating all three arrays on the Phase II HapMap data.
A full exploration of the utility of a SNP set involves estimating the power to detect
association under many study-design and disease scenarios' 4. Yet, a simpler, study-
independent measure of utility is the square of the correlation coefficient (r2) between
any observed marker and a putative causal allele 15. This metric is interpretable as the
expected drop in non-centrality of an association test statistic under specified
conditions' 6, and has become one standard for evaluating performance of marker sets172
Figure 1 shows the correlation between common SNPs in the Phase II data (i.e., SNPs
with minor allele frequency (MAF) 25%) and markers on the whole-genome arrays (see
Figure 1 legend for details). The fraction of SNPs captured is a function of the threshold
correlation coefficient required for tag SNP selection. For example, in the CEU panel,
45% of all common Phase II SNPs are captured by the GeneChip 500K array at r2 of 1
(i.e. no loss of power compared to testing the putative causal SNP directly); while 62% of
common SNPs are captured at r2 of 0.8 and 80% with r2>0.5 (i.e., highly significant
correlations to untyped alleles but with modest loss of power in association settings). As
expected, SNPs on the array capture a smaller proportion of variants in the most
genetically diverse panel, YRI when compared to CEU, CHB+JPT panels, in which the
fractions of SNPs captured are higher and similar to one another.
Figure 2 examines correlations of SNPs in the more fully ascertained ENCODE regions
for the GeneChip arrays. This cross-validates the results of common Phase II SNPs and
allows examination of a substantial, yet incomplete set of SNPs with frequency 1-5%.
The representation of the latter set of SNPs is limited and biased by the scope of SNP
discovery efforts, which tend to miss the rarer alleles. The examined set of SNPs
therefore reveals only an upper bound on the ability of the arrays to capture low
frequency alleles, which is nevertheless much poorer than corresponding ability for
common ones21. This highlights the focus of the array content at common variants, where
association studies are most powerful to detect (subtle) genetic effects 22. Comprehensive
scans for rare causal alleles will require other sets of markers, more involved analysis
methods23,24, and where possible, complete resequencing.
Even though a considerable fraction of common variants are captured by the current
generation of genomewide arrays, there exists a substantial component of common
variation not highly correlated to a SNP on each array. We set out to analytically improve
ability to capture common variants using only the SNPs on these arrays and knowledge of
LD in available HapMap data. Here we describe an approach in which HapMap data is
used to detect correlations between specific combinations of alleles for SNPs on each
array (called multi-marker predictors 20) and a putatively causal allele previously
uncaptured. We and others' 7 -20,25 have elsewhere introduced this concept in the context of
tag SNP selection, avoiding the typing of certain SNPs to improve typing efficiency
while maintaining study power. In the context of fixed-content SNP genotyping products
we propose to use specific multi-marker predictors of untyped SNPs (inferred from the
HapMap) as tests of association, thereby increasing study power without performing
additional genotyping.
We observe that multi-marker predictors based on combinations of alleles of 2 or 3 SNPs
can capture (at r2>0.8) an additional 9-25% SNPs in ENCODE or HapMap Phase II
(Figure 3). Notably, using these specific tests (fully listed online), the HumanHap300 and
GeneChip 500K arrays gain the ability to capture 80-86% of common alleles in the CEU
population with this high level of correlation. These tests also facilitate pooling
association results from studies that used different arrays, through combined predictions
of the same SNPs. This gain in power is achieved without any additional genotyping and
thus permits more comprehensive association studies with current products, at no extra
cost.
A possible concern is the potential of overfitting based on HapMap relationships
involving limited sample sizes (120 chromosomes for CEU and YRI, 180 chromosomes
for CHB+JPT). Mathematically, however, the chance of a highly correlated (r220.8)
common variant in this sample size is much smaller (<10-12) than the space of predictors
searched for each SNP. We verified this empirically by developing multi-marker
predictors to unlinked SNPs: we never observed spurious correlations of r2>0.35 in
HapMap data. While for rare alleles overfitting is indeed an issue using the HapMap
sample sizes, we are confident that relationships at thresholds such as r2>0.5 involving
common SNPs are robust and reliable.
These results suggest that in studies where direct typing of a common causal SNP would
be successful, use of one of these genotyping arrays would most often be successful as
well20 . Yet, focusing on scenarios where power is limited, the benefits of capturing more
variants by our method needs to be appraised versus the statistical cost of performing
additional hypothesis tests. This is because addition of statistical tests could, in principle,
lead to a reduction in power via the requirement of increased statistical significance
thresholds to maintain constant type I error rates (or, conversely, allowing substantially
more false positives if statistical thresholds are unchanged).
This tradeoff is of particular relevance to multimarker predictors, as they capture on
average fewer untyped SNPs than do single SNPs. That is, we observe that statistical tests
based on the genotype of a SNP on the array have more proxies on average in HapMap
Phase II than do statistical tests based on two and three marker haplotype predictors:
3.85 vs 1.55 putative causal alleles captured, respectively, on the GeneChip 500K array
in the CEU panel. At the extreme, testing all observed allele combinations2 6, rather than
only the SNPs and specified multimarker predictors might not pay off, as the dramatic
increase in degrees of freedom 18, 25 results in only a tiny increase in the fraction (3% in
CEU) of common SNPs captured 9. Adding many tests while increasing by a small
amount information capture can result in a loss of power for association to common
alleles'8 ,20
We consider a Bayesian strategy to tests all alleles without suffering from an increased
burden of multiple testing. The standard, frequentist strategy for genomewide association
studies8 assigns a 1- or 2-degree of freedom score to each variant tested and searches for
p-values deemed significant. While p-values speak to the extent of surprise by observed
data under the null (i.e., no association) hypothesis, external information may be quite
relevant to the alternative hypothesis (that the tested, or a nearby correlated, variant is
truly causal). Intuitively, not all tests are created equal - those hypothesis tests which
capture the genotypic variance at many SNP sites, or those which correspond to known
functional alterations, may rightly be considered more likely a priori to be true positives
than those hypothesis tests that capture only a single variant site (of unknown functional
significance). This highly relevant information is not customarily considered a priori in a
formal fashion (although often discussed in a post-hoc manner). Analysis of the HapMap
data makes it possible to incorporate such information up front in association analysis.
Specifically, we define prior probabilities based on the identities and number of putative
causal alleles captured by each allelic hypothesis test. Having assigned a prior probability
for each of being causal, we can evaluate the aposteriori likelihood of association given
the data (see Methods).
We demonstrate this framework using one objective, simple, and universal hypothesis
used in simulation studies20 ,26 - namely that each common SNP in the genome is equally
likely to be causal. The a priori likelihood of association to each marker on the array is
therefore proportional to the number of SNPs it captures. The number of variant sites
captured by each hypothesis test is highly variable, as even very large clusters of
correlated SNPs may be represented by a single SNP, while other SNPs capture only
themselves. We show by simulated association studies that incorporation of such
Bayesian priors (see Methods) modestly but consistently (and statistically significantly)
improves power to detect association as compared to a frequentist framework. For
example, association testing to 100 SNPs, chosen either randomly or by LD tagging, is
improved by 4% by this approach (Supplemental Figure 1). Moreover, the value of this
approach will only increase as genomic annotation improves the estimate of the prior
probability of each variant site in the genome being causal. Moreover, individual
investigators can tailor analysis based on their own views of how to weight SNPs that are
coding27, associated with variation in gene expression, under a compelling linkage peak28,
or in genes whose function is tied to a particular pathway.
Discussion
The simultaneous emergence of genomewide genotyping arrays and comprehensive,
deeply ascertained SNP data from HapMap provides for the first time a toolkit to evaluate
association between common genetic variation and disease throughout the genome. We
find that current products capture a sizeable portion of genomic variation, and describe
methods to utilize the HapMap data for testing additional non-array SNPs in silico
without further genotyping. Finally, we have developed a framework to prioritize the
tested SNPs based on external information provided by HapMap and, potentially,
additional genomic annotation. Such methods should help enable systematic and more
powerful evaluation of the contribution of common alleles to complex phenotypes.
Methods and Materials
Data sets
We used the phased ENCODE data from HapMap (release 16c. 1. We also used genotype
data from Phase II HapMap (release 19), and merged these with the genotype data
generated by the GeneChip 500K array, ported the data to NCBI build 35 (UCSC hgl7),
and subsequently phased the final data using the EM algorithm 29.
Choosing multi-marker predictors
For every array product, we have specified a set of haplotype tests based on HapMap
using Tagger2 . For every SNP that is not typed on the array, we aim to find the allelic
test (predictor) with the highest r2 to it, exploiting the knowledge which SNPs are present
on the array. The predictors are identified by performing an aggressive search among
combinations of 2 or 3 SNPs (on the array), evaluating the r2 between the generated
haplotypes and the allele we want to capture. While many of the untyped SNPs are
captured by high pairwise correlation to a SNP on the array, a substantial fraction of the
(common) SNPs is not. We have made the multi-marker predictors for all three arrays
evaluated here available on our website.
Simulating case-control panels
Our simulation framework follows a recently published protocol 20. Briefly, the phased
ENCODE chromosomes (n=120 from unrelated individuals in CEU) were resampled to
create 1000 cases and 1000 controls (4000 chromosomes in total). For controls,
resampling was uniform. For cases, we designated one SNP to be causal. For this causal
SNP, we calculated an effect size (and corresponding allele frequency in the cases) such
that if it were to be the only SNP tested, power would be 95% to detect it at a nominal P
value of 0.01. In terms of relative risk, the simulated effect size was therefore larger for
rare alleles (see Supplemental Fig. 2). We created 250 case-control panels for each causal
SNP, where we allowed, at random, either allele of a given SNP to be causal. We
repeated this for all common SNPs in a region, and for all ten ENCODE regions
separately (a total of nearly 10,000 SNPs). We also generated 250,000 null panels
(without a causal SNP) for evaluation of the null distribution.
Power calculations
Power is defined as the fraction of the simulated case-control panels in which the test
statistic exceeds the significance threshold (when an association can be declared),
averaged over all ten ENCODE regions. We use the maximum of the 2x2 chi-square
comparison over all allelic tests (single-marker tests and optionally the specified multi-
marker tests) as the region-wide test statistic. The significance threshold is derived by
performing the same allelic tests from the null panels (to achieve a region-wide corrected
P value of 0.01). The absolute power to detect association at P < 0.01 after multiple
testing correction is 68%, if all common SNPs are evaluated. Power remains >90% of
this figure when the best tags (with most proxies) are selected at a density of 1 per 5 kb, if
these tests are given uniform weights20 . Introducing weights based on LD improves
power.
Derivation of weights for allelic tests
Suppose the set of m putative causal alleles is A = {a,...,am }. Denote by C[a,,I] the
count of the allele at in a set I of individuals. Let 1i, Io be sets of cases and controls, of
sizes N1, No, respectively. Define the normalized difference statistic
C[a,,11] C[a,,I0]
Z(a,)= N No
(C[al]+C[ao (- C[a, ] + C[a, N I0iiNi + N, o
Suppose further that the set of n tests (single- or multi-marker predictors) used to capture
these alleles is T = fto,...,t, }, and extend the definition of the count operator [] and the
statistic Z to these tests.
The null hypothesis is simple: Z(t,),...,Z(t,) are all standard normal variables (a.k.a. z-
scores). In contrast, the alternative hypothesis is complex: it states that a causal allele is
chosen out of A according to some prior distribution D: A -+ [0,1] (where D(a1 ) denotes
the probability of at to be chosen as causal) and given that choice, all tests that are
correlated with ac are normally distributed with means greater than zero. More
specifically, let u, be the effect size for the causal allele ac , represented in terms of mean
offset of Z(ac) from the origin. For each test tj, let r,,j denote its correlation coefficient
to a . Hence, if a, is causal, Z(t1) is normally distributed with mean pc -r,'j.
In this study we denote the normal p.d.f. and c.d.f. by 0 and ,D respectively. We use the
simulation assumption 20 that cu, = 1(0.95) + 0(0.99) z 3.97. We use Haploview 30 to
compute the matrix R = Kre,, ]xn of correlation coefficients between all tests and all alleles,
and transform it into a matrix W = [wi,j lxn where w,,j is the probability that given a, is
causal, it will be detected by t , i.e., the top scoring test for a, is tj , and it is above the
null signal. Formally, if r,, = 0, we set w,,j to zero as well. Otherwise, to compute wi,j we
integrate over the real signal, Z(a,) , given which we can write down the score
distributions of the current test t, and the scores in needs to exceed: the null signal, as
well as any true signal by some other test ti, correlated to a,. We approximate such tests
as being dependant through a, only. We can thus express all relevant probabilities as
functions ofZ(a,), as follows:
wiJ =  P(Z(tJ)> null I Z(ai)= z) I r P(z(t)> z(t)> IZ(ai) = z)J (z-i)dz =
Z=-ýQ ( Ir x*o, jg j'
=ri,j,*O,j j' 2 - -rj j,
where null represents the region maximum score in a null panel and Pnui (z) is the
empirically derived c.d.f. of this maximum. We can now write the likelihood ratio test for
a dataset with the maximum-scoring test tj achieving an observed score zj:
Pr[Z(t)-= z , I H 1]-
.,We thus compute a weight factor W, = (D(a,
S i=
that to prioritize all p-values.
). wi, ) for each test tj employed, and use
o z -_ )dz
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Figure 1: Fraction of common (MAF >_5%) Phase II HapMap SNPs (y axis) captured by array SNPs
as a function of the r2 cutoff (x-axis). Data is presented for the GeneChip 100K (dash-dot line), GeneChip
500K (solid line) and HumanHap300 (dashed line) arrays, for each of the three HapMap analysis panels:
Yoruba people ascertained in Ibadan, Nigeria (YRI; left; green); The CEPH collected samples of European
ancestry, ascertained in Utah (CEU; middle; orange); and Han Chinese samples from Beijing with Japanese
samples from Tokyo (CHB+JPT; right; purple).
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Figure 2: Fraction of SNPs (y axis) captured by SNPs on GeneChip 100K and 500K arrays as at r2 >
0.8 in the three HapMap panels: YRI (left) CEU (middle) and CHB+JPT (right). Data is presented for
common SNPs (dark bars) as observed in HapMap Phase II and ENCODE and less common (MAF 1-5%)
SNPs (light bars) as observed in ENCODE. As ENCODE data do not fully represent SNPs from the latter
category, but rather includes only a partial set of such SNPs that happened to have been discovered (and
tend to be more common), results presented here should be considered as upper bounds for the ability to
capture the complete set of alleles of frequencies 1-5%.
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Figure 3:Fraction of common SNPs (y axis) captured by single array SNPs vs. multi marker
predictors in three HapMap panels (YRI - left; CEU - middle; CHB+JPT - right). Data is presented for
HapMap Phase II (top) as well as ENCODE (bottom). For Phase II data, we evaluated the GeneChip 100K,
GeneChip 500K and HumanHap300 arrays with 2-marker predictors. In ENCODE, we evaluated the
GeneChip arrays with 2- or 3-marker predictors. Since SNP selection for the HumanHap300 product is
based on LD information from Phase I HapMap data (including ENCODE ), evaluation using this dataset
would be biased upwards, and is therefore omitted. We report results only for common SNPs in order to
minimize risk of overfitting in the multimarker predictors and thus overestimation of ability to capture rare
alleles.
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Supplemental Figure 1: Power of a Bayesian approach (using variable weights of the allelic tests of
association) vs. the existing, frequentist approach (employing uniform weights) in simulated association
studies with either SNPs selected at random or LD-based tag SNPs, at a density of 100 SNPs per 500kb
ENCODE region. Power is computed by simulating case-control association studies on resampling of
haplotypes in CEU. Results are averaged over all ten ENCODE regions.
Supplementary Figure 2: Same as supplementary figure 1 in Chapter 2
100-
80-
60-
40-
20
=n i
a
-ior
EL
a-
1uu0
80
v A
·8~·s~~
_•,.,6" ,K%
[
References
1. Devlin, B. & Risch, N. A comparison of linkage disequilibrium measures for fine-
scale mapping. Genomics 29, 311-22 (1995).
2. Risch, N. & Merikangas, K. The future of genetic studies of complex human
diseases. Science 273, 1516-7 (1996).
3. Collins, F.S., Brooks, L.D. & Chakravarti, A. A DNA polymorphism discovery
resource for research on human genetic variation. Genome Res 8, 1229-31 (1998).
4. Wheeler, D.L. et al. Database resources of the National Center for Biotechnology
Information. Nucleic Acids Res 34, D173-80 (2006).
5. Gunderson, K.L., Steemers, F.J., Lee, G., Mendoza, L.G. & Chee, M.S. A
genome-wide scalable SNP genotyping assay using microarray technology. Nat
Genet 37, 549-54 (2005).
6. Matsuzaki, H. et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide
arrays. Nat Methods 1, 109-11 (2004).
7. Reich, D.E. et al. Linkage disequilibrium in the human genome. Nature 411, 199-
204 (2001).
8. Hirschhorn, J.N. & Daly, M.J. Genome-wide association studies for common
diseases and complex traits. Nat Rev Genet 6, 95-108 (2005).
9. Altshuler, D. et al. A haplotype map of the human genome. Nature 437, 1299-320
(2005).
10. Kruglyak, L. Power tools for human genetics. Nat Genet (2005).
11. Carlson, C.S. et al. Selecting a maximally informative set of single-nucleotide
polymorphisms for association analyses using linkage disequilibrium. Am J Hum
Genet 74, 106-20 (2004).
12. Kruglyak, L. & Nickerson, D.A. Variation is the spice of life. Nat Genet 27, 234-
6 (2001).
13. Pe'er, I. et al. Biases and reconciliation in estimates of linkage disequilibrium in
the human genome. Am J Hum Genet 78, 588-603 (2006).
14. Purcell, S., Cherny, S.S. & Sham, P.C. Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits. Bioinformatics
19, 149-50 (2003).
15. Pritchard, J.K. & Przeworski, M. Linkage disequilibrium in humans: models and
data. Am JHum Genet 69, 1-14 (2001).
16. Sham, P.C., Cherny, S.S., Purcell, S. & Hewitt, J.K. Power of linkage versus
association analysis of quantitative traits, by use of variance-components models,
for sibshtip data. Am J Hum Genet 66, 1616-30 (2000).
17. Crawford, D.C. et al. Haplotype diversity across 100 candidate genes for
inflammation, lipid metabolism, and blood pressure regulation in two populations,
Am J Hum Genet 74, 610-22 (2004).
18. Chapman, J.M., Cooper, J.D., Todd, J.A. & Clayton, D.G. Detecting disease
associations due to linkage disequilibrium using haplotype tags: a class of tests
and the determinants of statistical power. Hum Hered 56, 18-31 (2003).
19. Weale, M.E. et al. Selection and evaluation of tagging SNPs in the neuronal-
sodium-channel gene SCN IA: implications for linkage-disequilibrium gene
mapping. Am J Hum Genet 73, 551-65 (2003).
20. de Bakker, P.I. et al. Efficiency and power in genetic association studies. Nat
Genet 37, 1217-23 (2005).
21. Clark, A.G., Hubisz, M.J., Bustamante, C.D., Williamson, S.H. & Nielsen, R.
Ascertainment bias in studies of human genome-wide polymorphism. Genome
Res 15, 1496-502 (2005).
22. Pritchard, J.K. & Cox, N.J. The allelic architecture of human disease genes:
common disease-common variant.or not? Hum Mol Genet 11, 2417-23 (2002).
23. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting
from frequent nonsense mutations in PCSK9. Nat Genet 37, 161-5 (2005).
24. Cohen, J.C. et al. Multiple rare alleles contribute to low plasma levels of HDL
cholesterol. Science 305, 869-72 (2004).
25. Stram, D.O. et al. Choosing haplotype-tagging SNPS based on unphased genotype
data using a preliminary sample of unrelated subjects with an example from the
Multiethnic Cohort Study. Hum Hered 55, 27-36 (2003).
26. Lin, S., Chakravarti, A. & Cutler, D.J. Exhaustive allelic transmission
disequilibrium tests as a new approach to genome-wide association studies. Nat
Genet 36, 1181-8 (2004).
27. Botstein, D. & Risch, N. Discovering genotypes underlying human phenotypes:
past successes for mendelian disease, future approaches for complex disease. Nat
Genet 33 Suppl, 228-37 (2003).
28. Roeder, K., Bacanu, S.A., Wasserman, L. & Devlin, B. Using linkage genome
scans to improve power of association in genome scans. Am J Hum Genet 78,
243-52 (2006).
29. Excoffier, L. & Slatkin, M. Maximum-likelihood estimation of molecular
haplotype frequencies in a diploid population. Mol Biol Evol 12, 921-7 (1995).
30. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21, 263-5 (2005).

Chapter 5: Estimation of the Multiple Testing Burden for
Genomewide Association Studies of Nearly All Common
Variants
Copyright notice: Material in this chapter appeared originally in
Pe'er I, Yelensky R, Altshuler D, Daly MJ.
Estimation of the multiple testing burden for genomewide association studies of nearly all common
variants. Genet Epidemiol. 2008 May;32(4):381-5. PMID: 18348202 [PubMed - in process]
Copyright © 2008 John Wiley & Sons Inc
Reprinted with permission of Wiley-Liss Inc. a subsidiary of John Wiley & Sons Inc. (see appendix)
Introduction
Whole Genome Association Studies (WGASs) are examinations of a dense set of SNPs
across essentially all available regions of the genome to survey much of common genetic
variation for a role in heritable disease traits. WGASs (Hirschhorn and Daly 2005) offer a
systematic strategy to assess the influence of common (minor allele frequency > 5%)
genetic variants on phenotypes (Risch and Merikangas 1996). Although the number of
SNPs typed in such a study may vary, typically between 105 and 106 SNPs, statistical
analysis often involves additional testing, so that number of added tests dominates the
number of typed-SNPs tested. This additional testing may involve consideration of
combinations of typed, promising SNPs that predict nearby alleles in the original samples
(Klein et al. 2005) (Wellcome Trust Case Control Consortium 2007), of experimental,
second stage typing of such alleles in additional samples (Arking et al. 2006) or of
additional sets of SNPs typed in another study for joint analysis (Saxena et al. 2007; Scott
et al. 2007; Zeggini et al. 2007) . In all these scenarios, the WGAS aspires to test
association to more variants than physically typed, ideally testing all common variants in
the genome. Most variants tested will not be associated to any particular phenotype, but
may produce false positive association signals, masking potential true positives.
Forecasting the null-distribution of these false-positives is important as a practical
guideline for interpreting genomewide association scans, akin to classical work (Lander
and Kruglyak 1995) directing genomewide linkage analysis of indirectly typed variants.
The concrete question is, given an association signal of a certain nominal p-value, how
unlikely is it in a WGAS that attempts to examine all common variants?
Results
The number of SNPs on the array may guide multiple testing correction if only these
SNPs are tested for genetic association. In contrast, we focus on testing not only typed
SNPs, but also most other common variants in the genome. Naive, Bonferroni (Sidak
1967) corrections for standard testing of multiple, independent hypotheses are
overconservative in this context: local correlation among these tests means that
effectively there are considerably less independent tests than Single Nucleotide
Polymorphisms (SNPs) examined. Theoretical (Tavare et al. 1997) and simulation studies
(Lin et al. 2004) relate the number of such tests to the number of historical
recombinations, estimated to be much smaller. Yet, no previous systematic evaluation of
the testing burden is available on a dense dataset that can mimic fine mapping on a near
complete scan of variation, such as the second stage in a multi-staged design.
Such an evaluation is particularly critical to study designs that include a second stage of
additional genotyping (Thomas et al. 2004; Skol et al. 2006) or analysis (Klein et al.
2005) around putative causal SNPs that are proposed by the first stage analysis, as these
designs do not trivially lend themselves to significance evaluation by permuting
phenotypic labels. For 2-stage genotyping designs, common variation is first screened for
association signals using cost-effective typing of hundreds of thousands of SNPs (Barrett
and Cardon 2006; Pe'er et al. 2006 ). Next, regions of potentially positive signals are
followed-up with denser, saturated SNP sets, in order to validate, refine and strengthen
the associations. As well worked out in linkage analysis (Kruglyak and Daly 1998), this
directed increase in marker density around positives alters the null signal distribution
with the practical effect of mimicking a WGAS of all 6-7 million common SNPs. Hence,
permuting 1St-stage data with only the smaller, typed set of SNPs underestimates
expected false positives. Permuting the 2 nd stage data is possible only for the regions that
were followed up, therefore impossible to implement in a nested fashion for every
permutation run of the 1st stage.
Implementation of a permutation procedure for study designs with a 2nd stage of analysis
in promising regions requires rigorous, automatic criteria for such followup. Since 2"nd
stage analysis may be based on post-hoc review of the associated region, pinning down
the desired followup criteria in an objective fashion is challenging.
The testing burden associated with examining all common alleles does lend itself to
empirical evaluation from data, thanks to the Human Haplotype Map (HapMap)
ENCODE regions (Altshuler et al. 2005). These regions offer near-complete description
of common SNPs (Pe'er et al. 2006) across 1/600 of both the physical and the genetic
length of the genome. The demonstrated ability of these regions to represent LD among
common variants across the genome (Pe'er et al. 2006) (Altshuler et al. 2005) allows
their use for simulating association studies with no true signal (de Bakker et al. 2005).
More specifically, we generate the genetic data for a simulated (case or control)
individual at an ENCODE region by randomly pairing two of the phased chromosomes
available from HapMap trio parents for that region. We repeat this to obtain 2000
individuals randomly labeled cases or controls, mimicking a null study. The maximal Z-
score difference in allele frequencies between "cases" and "controls" across all SNPs in
such a region is evaluated for significance, and the p-value distribution is estimated by
repeating the simulation N=107 times. This distribution observes more significant p-
values then theoretically distributed p-values for a single test statistic due to multiple
testing. We repeat this evaluation procedure for the trio-base HapMap populations (CEU
and YRI), for all ENCODE regions, and for different cohort sizes. The per-region testing
burden is the factor by which significance is exaggerated. As ENCODE regions represent
the genomewide average recombination and mutation rates, we propose ENCODE-based
extrapolation to estimate the genomewide testing burden in such an association study.
We now outline a formal procedure for estimating testing burden. Suppose the simulation
considers a region that spans a fraction g=1/600 of the genome (all ENCODE regions
totaling 5Mb). For a nominal p-value p that is computed from the theoretical distribution
of the association statistic, we tally n(p), the number of studies out of N simulated, at
which the best regionwide nominal p-value reaches or exceeds p. n(p)/N is therefore an
estimator of the permutation-based p-value regionwide. The expected number H of hits -
regions that have a SNP whose score exceeds p - across the genome is therefore
H(p)=n(p)/gN. Testing burden is defined to be the ratio between the nominal and
permutation-based p-values: n(p)/pN regionwide, or n(p)/pgN genomewide. This can be
estimated for every p. Choosing p such that H(p)=0.05 would be relevant for the
genomewide significance threshold in the initial cohort, whereas H(p)>1 would be
relevant to a 2-stage design that carries over H(p) false-discovery loci to be typed in
additional samples. We chose the middleground, focusing on the value p relevant for a
single null hit genomewide. This is motivated by two potential practical outcomes of a
study. If a study includes several positive findings, false discovery rate will be much
lower than one even when H(p)= 1, motivating interest in SNPs at that significance level.
Alternatively, even in studies consistent with the null hypothesis of no association, this
significance level is interesting, as it is approached or attained by the top SNPs that are
the most suggestive candidates such a study may propose for additional investigation. We
note that this threshold does not formally control familywise error rate, nor false
discovery rate, and is intended to provide practical guidelines, rather than be taken
literally.
We observe that when H(p)=l, the genomewide burden is simply 1/p. Putting this
observation to practical use, we sort the N respective top single-hits in each of the
simulations from the smallest (most significant) to the largest. We choose p to be the gN-
th value up this list, and report the reciprocal as the testing burden. We note that for a
single ENCODE region the expected number of runs achieving such a p-value amongst
500kbN=10 7 simulations is gN = x 107 1700, and the standard deviation of this number
3Gb
is a = Jg(1- g)N 40. This provides a practical way to estimate confidence in
estimating the gN-th order statistic due to the number of simulations being finite by
considering (gN-2a)-th and (gN+2c)-th order statistics. Another source of sampling error
has to do with the small fraction of the genome being analyzed. The differences in
estimation across ENCODE regions can guide us with respect to this sampling error.
Figure 1 a reports the extrapolated number of independent tests required to mimic the
expectation of the best p-value in a WGAS, i.e. the empirical testing burden. For all
ENCODE SNPs, we find the testing burden to be around one million tests in the HapMap
European (CEU) samples, and for all common SNPs, we find the testing burden to be
roughly half million tests in the same population: considerably lower than available
bounds' that prove the number of edges in the Ancestral Recombination Graph to exceed
the number of independent tests in a dataset (Lin et al. 2004). As such edges can be
attributed to either splits or recombinations, their number depends on the sample size
(negligible in the context of the entire genome) and ancestral recombination events. The
formula Log(k)x NexR in (Tavare et al. 1997) estimates 1.1 million common
recombinations in Europeans, where: k is the number of coalescence branches
considered the reciprocal of the minor allele frequency threshold for sites considered, i.e.
k= 20 for common SNPs; Ne is the effective population size , -10,000 in Europeans; R is
the average number of recombination events per meiosis, 36.
A practical, first-cut guideline for correcting nominal p-values may be multiplying them
by this genomewide testing burden. This means, for instance, that the probability of a
WGAS in a European population that examines all common alleles to exhibit, by random
chance alone (no true genetic effect), a result with p-value<1007 is smaller than 0.05. In
the HapMap African (YRI) samples, that have more SNPs, and less linkage
disequilibrium, testing burden is higher at one million. Since ENCODE data are still
incomplete w.r.t. rare variants, they provide only a lower bound on their associated
testing burden, showing it to be more than 2-fold higher than for common alleles.
Testing burden varies across the different ENCODE regions, which may be expected
given that ENCODE regions deliberately represent a variety of genomic characteristics
(The International HapMap Consortium 2003). Empirical standard deviation across the
10 regions amounts to 19.6% of the testing burden, in both YRI and CEU populations
(Fig la), suggesting a standard error of 6.2% in estimating average testing burden from
10 regions. We have evaluated the sampling error due to finite number of simulation by
considering different order statistics as described above, and showed it to be smaller than
0.2%.We therefore ascribe most of the observed variation in estimates to sampling
different regions. Yet, the process of selecting of ENCODE regions made sure their
average GC content, gene content, recombination rate, etc. were similar to the
genomewide average (The International HapMap Consortium 2003). While we offer no
genomewide evidence that ENCODE is representative of the genome in terms of other
measures such as testing burden examined here, this premise had been adopted by others
using ENCODE data is used as a standard benchmark for estimating frequencies of
genomewide phenomenon in a wide domain of applications (Bimey et al. 2007)..We note
that testing burden is not strongly correlated neither with the actual number of common
SNPs in the particular region (R2<0.03), nor with the regionwide recombination rate
(R2<0.01; see Fig 1b). In retrospect, this justifies extrapolation of our measurements from
ENCODE to the entire genome by physical span.
It is important to realize that testing burden is not constant across p-values: association
signals with more extreme p-values involve more burden (Fig 1 c). This means that
accurately correcting statistical tests by a constant factor is impossible. Our simulations
validate the formal analysis of modeling multiple genetic tests (Dudbridge and Koeleman
2004)(Hirschhom and Daly 2005) in pointing out that restriction of such modeling to a
constant testing burden does not sufficiently capture the full correlation structure between
tests. There is no genomewide testing burden to fit all significance levels, but rather one
can correct for such multiple testing by a burden function which depends on the
significance level of interest. This means the best practice for correcting a nominal p-
value for the entire genome is to use a lookup-table, rather than a fixed correction factor.
In order to better understand the intuition behind this variable testing burden, we recall
that a constant testing burden arises in the context of independent multiple statistical
tests. In contrast, dense SNPs along the genome are partially and locally correlated to
varying extents. Formally, the pair (Za, Zb) of Z score statistics of two correlated alleles of
different, nearby SNPs, a and b, respectively, will have a bivariate normal distribution,
with mean (0,0) and covariance matrix r  1]. If the allele a is significantly associated,
showing a standard normal score Za=zo, then given this association, the allele b will have
a nonzero expected standard score, with the conditional distribution being
(Zb I Z a = zo)-~ N(rzo,l -r2). The chance ofb to achieve a's significance level is
Pr(N(rz,1-r )> zo)= -zo .The events Xb and Xb of a and b achieving this
significance level, respectively, thus have correlation
1-r 02
CoV(Xa,Xb) (--) {JVar(Xa)Var(Xb) (-)
which is decreasing with Zo . This means that the more significant is the p-value, the
lesser the correlation coefficient is, or in other words, the lower the significance the less
correction for multiple testing the correlated tests require.
Fortunately, in a 2-stage design of a WGAS, the first stage is designed for a true positive
to reach only a moderate p-value, expected to be achieved by numerous sites (Skol et al.
2006). Such a stage would require less correction for multiple testing than the final stage
aiming at genomewide significance.
Finally, studies of larger size show more burden of multiple testing (Supplementary fig
1). We hypothesize that this effect is also related to the increased power of larger studies
to distinguish highly- (but not perfectly-) correlated causal variants. An alternative
explanation is that this observed effect is an artifact of our oversampling design: Rather
than simulating data by a true bootstrap procedure that samples real data without
replacement for each simulated dataset. We are simulating datasets of thousands of
individuals based on 120 chromosomes only. We note that a similar result was not
observed in a similar set of oversampling analyses (Dudbridge 2006), suggesting
attribution of this increased burden to the density and redundancy of ENCODE data we
use.
Discussion
These and other results offer considerable understanding of the distribution of null signals
in idealized association studies. Practical association studies may exhibit more extreme p-
values then predicted by our study even without real effects due to demographical and
genotyping technology differences between cases and controls that create artifactual hits.
Furthermore only the accumulating experience in such studies will reveal more about the
complementary parameters describing the alternative hypothesis, which speak to the
number and strength of true signals. Together, the distribution of null and true signals
will enable rigorous decision whether a given result indicates true association.
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Chapter 6: Genetic Analysis of Human Traits In-Vitro:
Drug Response and Gene Expression in
Lymphoblastoid Cell Lines
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Introduction
Genetic mapping by linkage and association is an unbiased approach to discover genes
and pathways influencing disease traits and responses to drugs and environmental
exposures 1. Unlike model organisms that can be exhaustively phenotyped and readily
exposed to drugs and toxins in the laboratory, there are substantial limits to the
phenotypes that can be safely elicited or measured in human subjects. Thus, there would
be great value in a human in-vitro model that faithfully reflects both in-vivo genetics and
physiology while allowing for systematic perturbations and characterizations in high
throughput. Such a model would be particularly useful to study the function of sequence
variants mapped by whole genome association studies of common human diseases that do
not fall in obvious coding sequences 2-6, many of which are presumed to influence disease
traits by regulating gene expression.
One such model system has been proposed and extensively studied: EBV-transformed
lymphoblastoid cell lines (LCLs) derived from human B-lymphocytes 713
Lymphoblastoid cell lines have long been produced as renewable sources of DNA as part
of normal and diseased cohorts. Initially, LCLs derived from genotyped CEPH pedigrees
14 and HapMap participants 15 were used to identify genomic regions linked to and
associated with inter-individual variation in RNA transcript levels (these "expression"
QTLs are referred in the text below as "eQTLs") 16-19. A small number of such eQTLs
have been found to also be associated with human disease 20-22. Moving beyond studies
of gene expression, LCLs have also been used to attempt to identify genetic variants that
predict for response to radiation and drugs in vitro 23-26. The mapping of eQTLs and drug
response QTLs have been combined by some investigators, seeking non-random
relationships between genotypes at single nucleotide polymorphisms (SNPs), baseline
RNA levels, and response to chemotherapeutic agents 27,28. One study claimed
identification of eQTLs that explain up to 45% of the variation seen between individuals
in cell sensitivity to chemotherapy 28
The generality and utility of findings in LCLs is ultimately a function of how well the
biology and genotype-phenotype relationships of LCLs reflect reality in-vivo. While the
DNA sequence of an LCL is typically a stable representation of the human donor 29, little
is known about the stability and biological meaning of cellular traits studied in vitro.
The degree to which potentially confounding variables can influence LCL-based studies
has not been studied. There are many opportunities for non-genetic variability to be
introduced in the path from the whole human to LCL's in-vivo (Figure 1): the random
choice of which subpopulation of B-cells (i.e. naive B cells vs memory B cells vs
activated B cells with or without terminal differentiation) are selected in the process of
immortalization, the amount of and individual response to EBV, the history of passage in
cell culture and culture conditions, the laboratory protocols and reagents with which
assays are performed, and the measurements used to assess drug response and RNA
phenotypes.
We set out to map genetic contributors predicting in vitro drug response in LCLs with a
series of experiments designed to also address concerns about the potential for noise and
unmeasured confounders in such a complex model 30 . While our data is broadly
consistent with results of previous studies, we find that measurable confounders are a
stronger influence on drug responses and RNA levels in LCLs than are DNA variants.
Even after incorporating both SNP and RNA data in our model, few compelling
associations of SNPs to drug response were observed. Our study identifies and addresses
several potential issues in the design and interpretation of experiments that aim to find
relationships between DNA variants, expression levels, and drug response. As with in
vivo genotype-phenotype studies, larger samples sizes are required to elucidate true
relationships. Notably, this is not a comprehensive survey of all traits in LCLs, but rather
an in-depth analysis of several important traits that are readily measurable and
increasingly studied. Thus, there may well exist other traits that are more robust and less
influenced by confounders and noise. However, in so far as the traits we approached are
typical, the findings are germane to any in-vitro system used to study genotype-
phenotype relationships.
Results
Data Collected
We studied 269 cell lines densely genotyped by the International HapMap Project 31. Cell
lines were cultured and characterized at baseline for a variety of cellular phenotypes
including growth rate, ATP levels, mitochondrial DNA copy number, EBV copy number,
and measures of B-cell relevant cell surface receptors and cytokine levels. Each cell line
was exposed in 384-well plates to a range of doses for each of seven drugs selected based
on their divergent mechanisms of action and importance in clinical use for treatment of
B-cell diseases, focusing on anti-cancer agents: 5-fluorouracil (5FU), methotrexate
(MTX), simvastatin, SAHA, 6-mercaptopurine (6MP), rapamycin, and bortezomib. Drug
response was measured using Celltiter Glo, an ATP-activated intracellular luminescent
marker that, when compared to mock-treated control wells, can represent relative levels
of cellular viability and metabolic activity. RNA was collected at baseline and RNA
transcript levels were measured genome-wide on the Affymetrix platform.
Baseline characterization and plating for drug response experiments was performed using
batches of 90 cell lines from each HapMap analysis panel (CEU, JPT / CHB, and YRI)
on each of three experiment days. The order of cell lines within each panel was
randomized to avoid inducing artificial intra-familial correlation. Each drug was tested at
a range of doses around the expected IC50 as reported for the drug by the NCI DTP; each
dose of drug was tested in two wells per plate and on two separate plates. These replicate
measurements for each cell line allowed assessment of intra-experimental variation.
To evaluate day-to-day (i.e. inter-experimental) variation in all traits, a subset of 90 cell
lines (30 from each of the three HapMap panels) was grown from a fresh aliquot and the
entire experiment was repeated. To evaluate the effect of technical error on measured
RNA levels, a set of 22 RNAs previously expression profiled (using Illumina
HumanChip) at Wellcome Trust Sanger Institute (WTSI) (generously provided by
Emmanouil T. Dermatsakis) was included in expression profiling at the Broad on
Affymetrix arrays.
Data can be downloaded from the Broad Institute web site:
(http://www.broad.mit.edu/-yelensky/cell_linespaper/). Please see Materials and
Methods for details of QC, normalization, etc.
Cell line sensitivity to chemotherapeutic drugs
Gene mapping of drug response (or any cellular phenotype) in LCLs requires that the
phenotype be: (1) precisely-measured technically, (2) biologically reproducible across
independent experiments, and (3) remain relatively free from confounding factors. We
assessed each of these characteristics in turn before performing genome-wide association
scans.
To evaluate variability in drug response across replicate plates assayed on a given
experiment day (technical reproducibility), we calculated the "relative" response of a cell
line to a drug by measuring the (signed) distance of that cell line's dose-response curve
for the drug on a given plate to the dose-response curve for the drug averaged across all
cell lines assayed that day, in that replicate plate set. (The two replicate plates for each
cell line performed on an experiment day were arbitrarily placed into set A or B.) This
non-parametric approach allowed all drugs to be treated uniformly (see Methods) and
generated two data points per cell line, per drug, per day. We ranked the cell lines based
on their relative response in plate set A and separately based on values from plate set B.
The rank-correlation (Spearman's rho) for relative response across sets A and B was high
(rho=0.86 to rho=0.99, Supplemental Table 1), indicating that drug response on a given
day is highly reproducible.
To evaluate variability across independent experiments assayed on separate days
(biological reproducibility), we repeated the assay on a subset of-~90 cell lines (30 from
each of the three HapMap ethnic panels). We calculated the relative response of a cell
line to a drug on each day by measuring the (signed) distance of that cell line's dose-
response curve for the drug (estimated using all values on both plates) to the dose-
response curve for the drug averaged across all cell lines on that day, producing two
values per cell line per drug (day 1 and day 2). (At this point, we noted that our assays
for rapamycin and bortezomib suffered from weak response and strong dependence on
drug batch respectively, and these drugs were not studied further, see Methods for a full
account). For the remaining five drugs, cell lines were ranked based on relative response
on day 1 and again on day 2, and the rank-correlation (Spearman's rho) was calculated.
In comparison to the high technical reproducibility on a given day, drug response was
more variable across independent experiments (rho=0.39-0.82, Supplemental Table 2)
We next noted that the rank order of cell lines based on relative response was strikingly
similar between three drugs (5FU, 6MP, and MTX). In fact, the rankings of cell lines for
these three drugs were as similar as the cell line rankings for biological replicates of the
same drug on different days (Figure 2A and Supplement table 3). Furthermore, we found
a similar correlation of relative response to a distinct pair of drugs, 5FU and docetaxel, in
the publicly available data of Watters et al.25 (Figure 2B). (This correlation likely
explains why these investigators found linkage for both drugs to the same genomic
locus). While correlation in relative response to multiple drugs could, in theory, indicate
a shared genetic mechanism common to many drugs, it could also suggest the influence
of an experimental confounder that more strongly influences drug response than does
genetic variation.
Indeed, we found that just such a confounder, as the baseline growth rates of the
individual cell lines contributed to the above correlation between drugs (Figure 2C;
Supplemental Table 3). Growth-rate was modestly reproducible across days (rho=0.37),
though not significantly heritable (h2=0.4, pval=0. 1). The dependence of drug response
on growth rate in LCLs, though never previously reported, is unsurprising as all three
agents impact the cell cycle. Using a differential equation model of drug response
accounting for the kinetics of exponential growth under exposure to drug (see Methods),
we estimated a growth rate adjusted EC50 for each cell line for each of the three affected
drugs. This approach removed the bulk of the correlation between drug responses and
between drug response and growth rate (Supplement table 4), though some correlation of
responses persisted. Standard EC50s were fit for Simvastatin and SAHA.
Baseline ATP concentrations (i.e. the average of Celltiter glo values for all mock-treated
wells across both assay plates for each cell line in our drug-response experiments, see
Methods) were then found to be correlated to growth rate adjusted EC50s for MTX and
5FU (Figure 2D). We interpret such ATP levels as a relative measure of the gross sum of
metabolic activity combined across all viable cells within an assay well. Like growth
rate, ATP levels were reproducible across biological replicates (rho=0.6) but not
significantly heritable (h2=0.19, pval=0.38). After further adjusting the growth rate
adjusted EC50s for MTX and 5FU for ATP levels using linear regression, the correlation
across drugs was nearly abrogated (Supplemental Table 5).
Having adjusted for confounding due to growth rate and ATP levels where necessary, we
performed genome-wide association studies examining EC50s for each drug and SNPs
from HapMap Phase 2 with Minor Allele Frequency (MAF) >10% 32. We did not
observe any associations that surpassed genome wide significance (p-val < 5e-8). In
addition, the distributions of statistical association between SNPs and EC50s did not
significantly exceed expectation under the null. Our lack of evidence for association
between SNPs and drug responses is consistent with prior publications 24-28, none of
which identified specific SNPs with genome wide significance.
Variability in RNA expression
Previous studies observed baseline levels of RNA expression correlated with response to
cisplatin and etoposide 24,27,28. While associations with RNA levels need not imply a
causal relationship as a common experimental or confounding process could
simultaneously affect both RNA levels and drug response (Figure 6A), the subset of
causal associations that are influenced by genetic variation may be highlighted by
integrating information on SNP genotype, SNP associations to RNA levels (eQTLs), and
RNA correlations to EC50s (adjusted for growth rate and ATP levels where appropriate)
27,28. In other words, by examining a two-step model SNP -> RNA -> drug response,
power may be increased to detect SNPs that influence drug response through their effect
on RNA. We thus turned our attention to RNA measurements in LCLs.
As with drug response, measurements of RNA expression, to be biologically meaningful,
need to be reproducible between replicates on a given day, between experiments
performed on different days, and largely unconfounded by experimental artifacts. One
common metric for estimating reproducibility in expression data is to rank the level of
expression of all genes in a single hybridization, and to compare the rank of all genes in a
separate hybridization of either another aliquot of the same RNA (technical replicates) or
newly derived RNA from the same cell line on a different experiment day (biological
replicates). When we assessed the reproducibility of ranked RNA levels using this
common metric, we observed a high correlation between biological replicates, i.e.
samples that were independently thawed and profiled twice in our experiments (Figure
3A - black curve). Yet, we also saw a similarly high correlation between profiles from
any pair of unrelated individuals (Figure 3A - red curve) and even across human-derived
cell lines paired with chimpanzee-derived cell lines (Figure 3A - blue curve). These
observations simply reflect the unsurprising reality that inter-individual variation in the
level of a single gene is small compared to the overall dynamic range in expression levels
across all genes. Thus, reproducibility of the rank order of transcript levels across an
individual is uninformative with regard to mapping of DNA variants influencing specific
genes.
A more useful metric for gene mapping is the reproducibility in rank order of individuals
based on the level of expression of a given gene. If the level of a single RNA transcript
in one individual is reproducibly higher than the same RNA transcript in another
individual, then it may be possible to identify genetic variants contributing to inter-
individual variation of this RNA transcript (i.e. an eQTL). If variation of an RNA
transcript level among individuals is low relative to technical and biological noise,
however, then it will not be possible to map genetic influences for expression of the gene.
We performed such an analysis for each of the 3,538 genes expressed in the cell lines
(using standard criteria for Affymetrix expression arrays). The analysis used samples
from 49 unrelated individuals that were independently thawed, cultured and profiled on
two different days (Figure 3B). In contrast to the results in Figure 3A, we see that the
rank-correlation of individuals based on individual genes is typically modest (rho = 0.25-
0.3). That is, only a fraction of the 3,538 RNA transcripts examined in LCLs vary
enough in levels among individuals (relative to technical and biological noise) to be
reliably measured for association to genetic variants.
To parse out the contributions of technical vs. biological noise to this variation, we
examined the reproducibility of rank orders of cell lines when the same RNA sample was
profiled on two different platforms (thereby eliminating variability due to cell culture and
RNA isolation). Specifically, RNA for 14 unrelated individuals (from YRI HapMap
subset) and their expression profiles (generated using the Illumina system) were
generously provided by M. Dermitzakis (WTSI). These same RNA samples were
profiled at Broad Institute on Affymetrix microarrays. When we calculate the
reproducibility in the rank order of RNA samples based on these two cross-lab, cross-
platform technical replicates, we observe a median rank-correlation of rho = 0.55 (Figure
3C - gold curve). This is much higher than the corresponding biological reproducibility
(independently repeating cell culture and RNA extraction) for the cross-lab, cross-
platform comparison recomputed for the same 14 individuals (rho-0.2, Figure 3C),
demonstrating the substantial biological variation of RNA expression in LCLs, in
addition to the expected measurement error inherent in such experiments.
To limit the impact of technical noise, we restricted analysis to one thousand genes that
supported the greatest technical reproducibility in rank order of individuals (rho>-0.7,
median rho - 0.85). Genes excluded by this threshold include both those that are
technically well measured but invariant across individuals and those for which there
exists inter-individual variation but technical noise on one platform or the other
overcomes the signal. (As the WTSI performed four technical replicates while we
performed only a single technical replicate, the WTSI data had lower overall variance.)
Genes excluded by this filter typically varied less across individuals, particularly in the
better-measured WTSI dataset. (median standard deviation of 1000 best-measured genes
= 0.27 vs 0.17 for the other -2500 expressed genes; p-val<le-15).
When analysis of reproducibility was limited to the one thousand genes with the highest
reproducibility in technical replicates, the correlation across biological replicates was
improved but still modest (rho=0.55, Figure 3D - cyan). That is, despite excellent
technical reproducibility (panel 3A) even relative to inter-individual variation (Panel 3C),
the rank order of individuals based on most genes was only partially reproducible.
We reasoned that some of the biological noise might be due to other measured factors, as
had been the case for drug response. Above a threshold of 5% variance explained, growth
rate was associated with levels of expression for relatively few genes (<5%), but -15% of
genes showed association to EBV copy number (Figure 4A), some of which encoded for
proteins known to participate in transduction pathways downstream of EBV signaling.
Moreover, >25% of genes were associated with ATP levels (Figure 4B). In total, over
40% of genes have at least 5% of their variation in RNA levels associated with one of the
three measures above (Figure 4E).
The association of RNA levels to such factors could, in principle, represent intrinsic
characteristics of each LCL (which could potentially be due to inherited DNA sequence
variation, acting indirectly through susceptibility to EBV infection or inducing a
metabolic state). Alternatively, growth rate, EBV infection, and metabolic state could
simply represent experimental noise that obscures genetic contributions to gene
expression variation. Interestingly, measurements of EBV copy number, ATP, and
growth rate at Broad correlate with levels of RNA expression generated independently at
WTSI 18,19 (Figure 4F), albeit more weakly than for the expression profiles generated on
the same samples at the Broad. Thus, these confounders display a component intrinsic to
each cell line, not only noise.
To examine how much of the variability in gene expression could be attributed to
inherited DNA variation, and how much to other factors, we examined cis-eQTLs that
influence RNA expression levels in our experiment. Using HapMap Phase 2 SNPs with
MAF> 10% that lie within a 0.15Mb window around each gene, we performed standard
linear regression between expression values of that gene and SNP genotypes coded 0,1,2
(representing the number of minor alleles carried by the individual). In our dataset, -9%
of genes harbored a cis-eQTL that explained at least 5% of the gene's variance in
expression levels in excess of the fraction of genes showing such association in permuted
datasets (Figure 4C). Even more eQTLs were evident in the WTSI expression data
(which employed four technical replicates), in which >20% of genes were associated with
a SNP that explains 5% or more of the variance (Figure 4D). Consistent with previous
analyses 16-18, in both data sets RNA transcript levels for a small fraction of genes were
associated with a cis eQTL that explained a large proportion of the variance. Moreover,
the overall proportion of genes that showed association to growth rate, EBV, and ATP far
exceeded the proportion associated to a cis-eQTL of the same strength (compare figure
4E to 4C).
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Inter- and Intra- individual variance component analysis
To parse the association of SNPs and other measures to variation in gene expression
further, we decomposed the total variance in expression of each gene into components
contributing towards inter-individual versus intra-individual (experimental) variation.
When we examine the effect of each cis-eQTL, growth rate, EBV copy number and ATP
levels on each variance component (see Methods), as expected, eQTLs contribute only to
inter-individual variation (Figure 5A). EBV and ATP, on the other hand, influence either
inter-individual or intra-individual variation, depending on the gene (Figure 5B and 5C).
Taken together, these observations have a number of implications: First, more genes are
associated with the measured non-genetic cellular factors than are associated with
individual cis-eQTLs. Second, these non-genetic factors influence gene expression not
only by varying across cell lines in a reproducible manner (like SNPs), but also by
varying across experiments for the same cell line. Third, for some genes, a given non-
genetic factor is associated only with inter-individual variation (genes arrayed along the
x-axis in Figure 5), and yet for other genes that same factor is associated only to intra-
individual variation (genes arrayed along the y-axis). Factors that are associated with
inter-individual variation could, in principle, represent causal processes related to the
action of a genetic variant, whereas those that only vary across experiments represent
noise with respect to genotype-phenotype correlation.
Having characterized non-genetic influences on levels of RNA expression, we proceeded
by looking at variation in RNA expression levels to understand its contribution to the
variation observed in drug response. Consistent with prior reports, we observed a large
number of genes whose level of RNA expression at baseline was correlated to drug
response. Levels of RNA transcripts for 20% of genes in the Broad Institute dataset and
18% in the WTSI dataset were associated (at a rho^2>0.05) to growth-rate and ATP
adjusted EC50 of at least one of the drugs assayed. EC50s for SAHA and 5FU appeared
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to have the strongest relationship to RNA levels, correlating to 8.7% of genes measured
at the Broad and to 7.7% of genes measured at WTSI.
Applying the variance components analysis to see how inter- and intra- individual
variation in growth-rate and ATP adjusted EC50s are influenced by RNA levels (and
"assigning" to a given gene its strongest correlated drug), we observed that RNA levels
are predominantly associated with inter-individual differences in EC50s (Figure 5D).
Much less of the correlation between RNA expression and EC50s reflects intra-individual
variation.
This observation that variation in RNA levels mainly influences inter-individual variation
in EC50s allow us to hypothesize that eQTLs for such RNAs could be used to identify
genetic contributors to drug response.
Integrating data from eQTLs and drug response in LCLs
Given that we observe significant correlation of both SNPs to RNA expression levels
(eQTLs) and RNA levels to inter-individual variation in drug response,
we sought to increase confidence regarding SNPs modestly associated with drug response
by combining evidence from the two relationships. The hypothesis we hope to prove is
that the RNA-drug response relationships are causal (i.e. eQTLA and RNAA in figure
6A), and thus eQTLs for these RNAs are causal influences on drug response themselves,
and can be detected by following the path from genetic variant to RNA level to drug
response phenotype. The "null" hypothesis is that the association of SNPs to RNA levels
and of RNAs to drug response are orthogonal and independent. (i.e. eQTLB and RNAB in
figure 6A). Under this scenario, the apparent correlation between RNA level and drug
response is induced by another factor (a non-genetic confounder), and there is no actual
causal link between RNA and drug response directly.
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To test these hypotheses, we set out to examine the fraction of genes whose expression is
influenced by an eQTL and correlated to drug response. As seen in Figure 4, -14% and
4.5% of genes have cis-eQTLs (r^2>0.08, FDR<10%) in the WTSI and Broad Institute
datasets respectively. At the same time, 18% (WTSI) and 20% (Broad) of genes are
correlated to drug response (rhoA2>0.05, FDR<1 0%). When we consider the intersection
of eQTL-bearing genes and drug-response correlated genes in each dataset
independently, we see that 1.4% (WTSI) and 0.9% (Broad) of genes are both correlated
to drug response and bear a cis-eQTL. Neither intersection contains more genes than
would be expected by chance alone (and only a small fraction of genes are involved),
suggesting that the effect of genetics of RNA expression on drug response is likely small.
Nevertheless, it is possible that some SNP-RNA-Drug response "tuples" contained in this
intersection are of type eQTLA and RNAA (from Figure 6A); if these can be distinguished
from others of type eQTLB and RNAB, it may be possible to discover true causal
relationships. To evaluate this possibility we focused on genes that both correlated to
drug response and bore a cis-eQTL among the set of 1000 "best-measured" genes in each
RNA dataset independently, yielding a total of 23 unique SNP-RNA-Drug response
tuples for examination.
If a SNP genotype induces differences in RNA levels of a gene between individuals, and
these RNA differences induce inter-individual differences in response to drug, we should
be able to observe significant association between SNP and drug-response directly.
Consistent with this idea, when we regress the drug EC50 against SNP genotype for each
of the 23 pairs above, we do see a modest degree of excess association (Figure 6B).
Moreover, the association appears to be in the expected direction, based on the directions
of the pair-wise relationships SNP-RNA and RNA-Drug response (Figure S ). Notably, a
simulated dataset with the same SNP/RNA/Drug variances and independent SNP-
RNA/RNA-Drug pairwise covariances (i.e. the eQTLB/RNAB scenario in Figure 6A) as
the real 23 tuples fails to demonstrate the excess association between SNPs and drug-
response we see in the real data (Figure 6B - gray lines). Though no highly significant
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examples were documented, these observations would appear to support the existence of
causal SNP-RNA-Drug response relationships (i.e. the eQTLA/RNAA scenario in Figure
6A).
In (Figure 6B) most p-values deviate (however modestly) from null, suggesting that
many may be causal. However, we recognize one oft-overlooked bias in this type of
analysis which introduces inflation to the SNP-Drug p-values in absence of (or in
addition to) real signal: the "winner's curse" 33 overestimate of effect size incurred during
discovery of eQTLs. Specifically, because we set a threshold (rA2>0.08) for the discovery
of SNP-RNA associations and because the bulk of the effect size distribution is at or
below this threshold, many of the identified associations (particularly those just crossing
the threshold) will have been identified because the true effect was overestimated by
chance (Figure S2). While the true portion of the SNP-RNA association does not cause
correlation between SNP and drug response, the chance correlation over and above the
true connection may also be correlated to drug response; that is, the SNP is by chance
correlated to orthogonal variance in the RNA, which could in turn be correlated to drug
response by another factor (the eQTLB/RNAB scenario). To bear this intuition out, we
replaced all real eQTL effects modeled in the simulation in Figure 6B with an eQTL
whose true effect is rA2=0.05, but only look at the subset of simulated datasets where the
observed effect is rA2>0.08. In this simulation, likely more representative of the
thresholded discovery overestimate of effect, we recreate an inflation of p-values similar
to that observed in the real data (Figure 6C).
Clearly, we would like to distinguish any true SNP-Drug response associations from
those that are spuriously inflated, but null. Unfortunately, because we don't know the real
effect sizes of discovered eQTLs, it is not possible to do so analytically. However, it is
helpful to consider what a real, causal SNP-RNA-Drug response tuple might look like. In
particular, we would expect the causal tuples with strong SNP-RNA associations to have,
on average, stronger SNP-Drug associations. Tuples where no causal relationship
between RNA and Drug response (and thus SNP and Drug response) exists would exhibit
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either strong SNP-RNA association or increased SNP-Drug association, but not both. If
we plot the strength of each eQTL against the strength of the SNP-Drug response
association, a striking picture emerges: most of increased association between SNP and
Drug response comes from the weaker eQTLs, while most of the stronger eQTLs have no
association to drug response (Figure 6D), consistent with the bias exposed above.
Additionally, an interesting group of 3 tuples emerges that are both relatively strong
SNP-RNA and SNP-Drug response associations (Figure 6D blue arrow). These are:
rsl384804-C8orf70 (Ensembl:ENSG00000104427)-MTX, rs3733041-GLT8D1
(Ensembl:ENSG00000016864)-5FU, and rs2279195-SH3TC 1
(Ensembl:ENSG00000125089)-Simvastatin with SNP-Drug p-values of 0.03, 0.05, and
0.02 respectively. We propose these are interesting candidates for follow-up and suggest
that similar analyses be carried out in future studies integrating genetic variation, RNA
expression, and other traits.
Discussion
Recent studies have shown that a substantial fraction of genes contain cis-eQTLs that
explain a modest fraction of inter-individual variation in RNA levels. Other studies used
LCLs to perform linkage and association scans for drug response traits 26-28. However,
few reports characterize the biological reproducibility of these phenotypes, and none to
our knowledge document their correlation to non-genetic factors such as growth rates,
EBV copy number, and metabolic activity. We document that most traits, whether drug
responses or RNA transcript levels, are only partially reproducible across experiments,
and that more genes are correlated to cellular growth rate, ATP levels, and EBV copy
numbers than to genetic factors (at comparable fractions of variance explained). Thus, in
addition to issues of statistical power relative to genetic size of effect, day to day
variability in a trait and confounding factors are major influences on gene mapping
experiments in LCLs. Though we looked at only a limited number of traits in LCLs
(response to seven drugs and RNA transcript levels), our findings are applicable to any
experimental system where genotype to phenotype correlations are studied.
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Consistent with prior reports, our genome-wide association studies of drug response did
not reveal any SNPs directly associated to drug response with genome-wide significance.
The inability to detect such SNPs is likely due to lack of power to detect small sizes of
effect with limited sample size and in the presence of significant confounding and noise.
Several studies attempted to improve power to discover SNPs associated with drug
response [15,16] by integrating data on RNA levels and eQTL mapping [18,19]. Whether
these eQTLs are incidentally or causally associated with drug response depends on
whether the cognate RNAs influence drug response or are merely correlated to drug
response by a non-genetic factor that simultaneously affects both phenotypes. Our results
show modest enrichment for association to drug response (EC50s adjusted for growth
rate and ATP levels) among eQTLs in genes whose RNA levels correlate to drug
response; most of this enrichment can be attributed to unavoidable biases in the analysis.
Accounting for these biases, our three most promising associations are rs1384804 near
C8orf70 to MTX, rs3733041 near GLT8D1 to 5FU, and rs2279195 near SH3TCI to
Simvastatin.
This result is similar to that recently published by Emilsson et al. 34 in which eQTLs for
genes whose RNAs were correlated to obesity were not convincingly associated to
obesity. Thus, while it is attractive to envision a general overlap between SNPs
associated to drug response or disease traits and those associated to RNA levels in
accessible tissues, empirical evidence for truly causal relationships remains anecdotal 22
Even in cases such as IRF5, where there is both strong association to disease and to RNA
levels in LCLs, the actual patterns of association to RNA levels and disease are quite
disjointed for the different mutations at the locus 21
A major limitation of the HapMap samples is their relatively small sample size for
performing a genome-wide association study. While better powered studies (such as
those proposed to study cell lines from eight thousand and one-hundred thousand
individuals by the Framingham Heart Study [29] and the National Children's Study [30]),
can certainly address the power issue, these larger studies face even greater challenges in
managing LCL culture conditions and experimental confounders in high throughput to
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minimize bias and noise 30. By highlighting these aspects of the LCL model, as well as
tackling how some of them can be addressed, we hope to build a stronger foundation on
which these important experiments can be planned and carried out.
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Methods and Materials
Cell Culture
EBV-transformed lymphoblastoid cell lines were acquired from the NHGRI Sample
Repository for Human Genetic Research in frozen aliquots. Cells were thawed in 5mL
culture medium (RPMI medium 1640 (Invitrogen) supplemented with 10% FetalPlex
(Gemini), 2mM L-Glutamine (Invitrogen), and lx penicillin/streptomycin (Invitrogen)).
Cell lines were counted daily using Z2 Coulter Counter (Beckman Coulter) and passaged
as needed to maintain a concentration of 2-5 x 1e5 cells/ml at 37C in a 95% humidified
5% C02 atmosphere.
Initially, cells were grown until 5 x 1e5 cells/ml were reached in 50 mL total volume.
Then, ten identical aliquots were frozen in 1 mL freezing media containing 50%
FetalPlex, 40% RPMI 1640 medium, and 10% DMSO (Sigma) at -80C for 24 hrs and
transferred to liquid nitrogen. These aliquots were used to provide biologic replicates for
the experiments described below.
Aliquots were thawed on experiment day #1 as described above. Cell lines were counted
daily and passaged as need to maintain a concentration of 4-8 x le5 cells/ml in 10 mL
culture medium. On experiment day #7, cells were counted and distributed for use in the
various experiments described below. One cc of culture was used for immediate
immunophenotyping via FACS and Luminex beads. One cc of culture was used for
RNA and DNA extraction using Trizol (Invitrogen) following the manufacturer's
protocol. The remaining eight cc of culture were used for drug response assays described
below.
Drug Response Assay
The drugs that we studied are bortezomib (courtesy of T. Hideshima), rapamycin
(Biomol), 5-fluorouracil (Sigma), methotrexate (Sigma), 6-mercaptopurine (MP
Biomedicals), SAHA (Biovision), and simvastatin (Calbiochem). These drugs were
arrayed in a source plate in the concentrations according to supplemental figure. The
source plate was pinned into each cell line in duplicate, resulting in each drug
concentration being assayed in each cell lines 4 times.
For drug response assays, LCLs for each cell line were diluted to 1 x le5 cells/ml, and
25 uL of cell culture were plated into each well of two white solid flat bottom 384 well
plates (Coming cat# 3704) using a microplate dispenser (Multidrop Combi, Thermo
Scientific). Next, 100 nL was pin-transferred from the source plates into the plates
containing cells using an automated 384 channel simultaneous pippettor (CyBi-Well,
CyBio). Plates were incubated at 37C in a 95% humidified 5% C02 incubator.
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After 48hrs, plates were removed from the incubator to room temperature for 10 minutes
prior to being vortexed for 30 seconds. 25uL of Celltiter Glo (Promega Cat No. G7573)
diluted 1:3 in PBS was added to each well with the Mutlidrop microplate dispenser and
shaken for two minutes. Luciferase luminescence was then immediately measured for
each well using a multiplate illuminometer (Envision, Perkin Elmer).
Raw data is publicly available online:
http://chembank.broad.harvard.edu/assays/view-project.htm?id= 1000477
The experiment was monitored for cell-culture handling, plating, pinning, and assay
errors and failed cell lines/plates/drug-rows were excluded from down-stream analysis.
(Most cell lines were successfully assayed on two plates for all drugs, however; specific
counts are below.)
Luminescence values in drug-exposed wells were divided by the median control-well
luminescence in the same plate row (after excluding plate edge wells) to obtain 4 viability
fractions per cell line, per drug, per dose, in each experiment. For evaluation of technical
reproducibility, the median of the 2 fractions on each plate was taken as the cell line's
response to that dose on that plate. For evaluation of biological reproducibility and all
other analyses, the median of the 4 fractions was taken as that cell line's response to that
dose in the experiment. Drug responses were examined, and it was noted that the
experiment failed to achieve meaningful cytotoxic response to rapamycin, with most cell
lines reaching a maximum fractional viability of only -0.6-0.7, even at highest
concentration of drug assayed. It was concluded that the viability assay was not a relevant
read-out for rapamycin response, and the drug was not considered in further analyses.
Overall cell line response to a given drug was then calculated by taking the average
response to a dose across all cell lines in the experimental batch (cell lines were assayed
in batches of--90), subtracting the average from the value for each cell line, and then
averaging the result for each cell line across all doses. (The 4-5 low-concentration doses
where all cell lines had a fractional viability of~- were excluded from the calculation.) In
this way, the (single value) relative response of a given cell line to a drug was calculated,
representing the non-parametric distance of that cell line's dose-response curve to the
average dose-response curve for that drug in the experiment. (For the analysis of
technical reproducibility, the calculation was done using only replicate plate A for all cell
lines, and then using only replicate plate B, and the two values were compared). Quality
control then proceeded by examining the dependence of response on the compound stock
plate from which the drugs were pinned. (Compound stock plates were prepared with
enough drug to run -20 cell lines and drug response should be independent of the drug
stock.) Indeed, it was noted that for 5FU, 6MP, Simvastatin, SAHA, and MTX,
dependence on drug stock was weak, while for bortezomib, the dependence was
profound, with large differences in response between different plates, significantly in
excess of the differences between cell lines on a given plate. Thus, bortezomib was
excluded from further analysis. Though dependence on compound plate for the other 5
drugs was weak, average response for each compound stock plate was subtracted from
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each cell line using that plate (for each drug independently) and this normalized response
was carried forward.
In summary, after the processing steps above in the main batch of experiments, 254 cell
lines were successfully assayed for response to 6MP, 256 for MTX, 260 for Saha, 262 for
Simva, and 259 for 5FU. 84 cell lines were then again successfully measured for all 5
drugs as biological replicates. (For ease of comparison, technical reproducibility is also
reported using only the two plates from these biological replicate samples.) These values
are available as "relative responses" in the online supplement. Analyses in Fig 2 use this
data for the -200 successfully measured unrelated individuals, after again centering
within each HapMap panel. Also, the median (non-boundary) control well luminescence
over the two plates for each cell line was taken as the "ATP content" of the cell line. The
value was divided by 100,000 and centered within each HapMap panel.
Modeling Drug response
To account for the effect of growth-rate on response to MTX, 5FU, and 6MP, we
reasoned as follows: Assume a simple ODE model of cell line population growth:
dP
= rP, where P(t) is the # of cells in the population at a given time, and r is thedt
(unobserved in the specific drug-exposure experiment) growth rate parameter. This ODE
has the solution: P(t) = Poe ' . When the cell line is exposed to drug, its growth-rate is
impaired in a concentration-dependent manner. Taking inspiration from first-order
Michaelis-Menten kinetics, we can model this as:
dPdrug - r( Max reduction * [ConcDrug]
dt Concentration for half maximal reduction aka " EC50"+[ConcDrug])
r MaxRed*[ConcDrug]ltwhich is solved by Pg (t) = Poe EC50+[ConcDrug] . As our observed luminescences are
which is solved by Pg(0 = P oeC
ratios between drug wells and control wells at given concentrations, we can write
r MaxRed*,ConcDrug] t
EC50+[C.oncDrug'] p -r*MaxRed*[ConcDrug]tPd5[(t) Poe Cncrg] )drug (t) ECO+[Concrug]
=P W , which can simplified as - EC50+[Concrug
P(t) Poe '  P(t)
There are two identifiable parameters in this model: the concentration necessary for half-
maximal reduction in growth-rate (EC50) which is independent of growth rate r itself,
and r * maximal reduction of r, a product term dependent on growth rate whose
components cannot be independently estimated. The model was fit for each cell line, for
each drug independently, using median measurements at all doses. QC was performed by
excluding all models with RSS>0.08. The -r*MaxRed term was discarded, and the EC50
was carried into further analysis after centering the values within each HapMap panel.
(257 cell lines were successfully fit for 5FU, 251 for 6MP, and 255 for MTX.) Models
were also successfully fit to all 84 biological replicates of 6MP and 5FU, and 82
replicates of MTX. ATP correction for 5FU and MTX was then carried out by taking the
residuals of the linear regression DRUG-ATP.
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SAHA and Simvastatin were modeled by a standard sigmoid35, with response (fractional
1- Max Inhibition
viability) at a given dose = Max Inhibition + . Notably, max1 + eslope*(log(dose)-log(EC50))
inhibition and EC50 are not the same as above, here representing a minimal viability and
the concentration at which that minimal viability is achieved, respectively. Maximum
inhibition (aka minimum viability) were <0.05 for most cell lines for simvastatin and
varied between -0. 1-0.3 for SAHA. The EC50 was carried into further analysis after
centering the values within each HapMap panel. Again, QC was performed by excluding
all models with RSS>0.08. (257 cell lines were thus successfully fit for Saha and 261 for
Simvastatin.) Models were also successfully fit to all 84 biological replicates of Saha and
5FU, and 83 replicates of Simvastatin. The GWAS for drug response was performed with
all successfully measured individuals, while analyses presented in Figures 2,5,6 were
performed with unrelated individuals only.
Growth Rate Measurements
Each cell line was seeded at a concentration of 2 x 1 e5 cell/mL in 2 mL. LCLs were
counted daily for five consecutive days with an automated particle counter (Z2 Coulter
Counter, Beckman Coulter). A regression of the form
log(conc day i) = r * i + log(conc day 0) was fit for each cell line to obtain the estimate of
growth rate r. QC was performed by evaluating the 95% confidence interval of the r
estimate and rejecting estimates whose interval width exceeded 1.1. Thus, estimates of
growth-rate for 237 cell lines were obtained. An abbreviated second replicate of the
experiment was repeated on a subset (155) of the cell lines with only the 3 rd day counts
collected to evaluate growth rate reproducibility.
FACS Analysis
From each LCL, -25,000 cells were incubated with R-Phycoerythrin-conjugated mouse
anti-human antibody to cell surface markers (CD19, CD20, CD21, CD40, CD58, CD80,
CD86, CD95, CD227, IgD, IgG, IgM, HLA-DQ, HLA-DR, and IL6R) at 40 C for 30 min.
Cells were washed once with PBS and 1% fetal bovine serum and were fixed with 1%
paraformaldehyde. Data on cell-surface expression in each cell line were acquired using a
fluorescence-activated cell sorter (BD Biosciences FACSCalibur system). To quantify
expression for each LCL, we used flow cytometry, requiring at least 500 cells per LCL
for it to be included in our analysis. Fluorescence intensity was measured for the anti-cell
surface protein antibody and a control isotype antibody for each LCL. A marker (and,
separately, a control) histogram was created by placing individual cell measurements into
1,024 equally spaced intensity bins. Counts in the control histogram were subtracted from
the marker histogram to obtained a "normalized" histogram of cell-counts in each of the
1,024 intensity bins. The average intensity was then calculated from this normalized
histogram and the log of this value was carried forward into QC as the average
normalized marker expression for that LCL.
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QC then proceeded by regressing this marker expression on the total cell count obtained
for that marker within a given experimental batch of LCLs. (samples were batched by
HapMap panel) We reasoned that if the experiment was successful, there should be no
dependence of cell-surface marker expression on the quantity of viable cells obtained in
the experiment; if there was such a dependence, the marker expression was likely reading
out handling differences between LCLs, not true, intrinsic differences in expression.
Indeed, by this metric, we found that during the first batch of experiments that was
attempted (for the CEU panel), only 4 markers were successfully measured, while
subsequent batches (YRI + CHB/JPT samples) succeeded for 14 and 9 markers
respectively. In most markers that passed this filter, it was further noted that a few cell
lines showed very low expression, far from the overall distribution of the values for each
batch. While it is conceivable that these represent true differences, we interpreted these
values as individual LCL measurement failures, and further truncated the lowest 5% of
values within each marker in each batch. Thus, the final dataset contains measurements
of: 85 cell lines for CD 19 and CD20, 169 for CD21, 166 for CD227, 248 for CD40, 164
for CD58, 166 for CD80 and CD86, 248 for CD95, 80 for HLADQ, 85 for HLADR and
IgM, and 165 for IgD, IgG, and IL6R. These values were centered within each panel and
carried into further analysis.
Luminex Assay
30 HapMap cell lines were screened with a multiplex antibody bead kit from Biosource
(Cytokine 25-Plex for Luminex (Catalog #LHC0009)). Of the 25 cytokines originally
selected for this assay, 8 were reliably detectable (lower concentration: IL8, IL 10,
IL12p40, TNFa, IP 10; moderate concentration: MIPla, MIP lb, RANTES). Of these, it
was found that measurements for MIP la and MIPlb were strongly correlated; thus we
decided to include only MIPlb in further experiments. These 7 cytokines were assayed in
the remainder of the cell lines according to the following protocol:
One cc for each LCL was placed into a single well of 96-deep well plate. The samples
were centrifuged at 500 rpm for 5 minutes at room temperature. The supernatant was
placed into a new 96-well plate, and placed dry ice to be stored at -80 degrees All assays
were performed on a single thaw.
The cytokines were measured following the manufacturer's protocol. In order to ensure
that the measured cytokine concentration fell in the linear part of the standard curve, the
lower concentration cytokines were multiplexed together (final dilution 1:2); and MIPlb
and RANTES were multiplexed together (final dilution 1:6).
The concentration of each cytokine was calculated based on the standard curve generated
by the same plate, after subtracting out the "blank" background. A 3-parameter model
was used to convert median fluorescent intensity (MFI) to protein concentration (ng / ml).
A subsequent correction was applied to account for the dilution factor at the time of the
assay. All final concentrations are expressed as pg / ml and log-transformed. 262 cell
lines were successfully measured for IL10, IL12, IL8, IP10, and TNFa, and 266
measurements were obtained for MIPlb and RANTES. (79 and 87 biological replicate
measurements were also obtained for the above two sets of cytokines respectively).
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RNA preparation and Affymetrix expression profiling
All LCLs were cultured in the fashion described above. Prior to the plating of cells for
the Drug Response Assay, 5 x 10/A5 cells were set aside for RNA extraction. Cells were
immediately lysed with Trizol Reagent (Invitrogen). RNA was collected according to the
manufacturer instructions. 1.25 ug total RNA (OD>1.8) was diluted to a total volume of
10uL. RNA was processed and hybridized onto Affymetrix Human U133A whole
genome RNA expression genechip@ arrays according to the manufacturer's protocol.
Gene expression summary values for the whole dataset were computed by RMA36,37 and
log-transformed. Measurements were successfully obtained for 257 HapMap cell lines in
the main experiment, for 64 biological replicates, for 24 cell lines originally thawed at the
WTSI, as well as multiple replicates of 5 cell lines derived from chimpanzees. (raw data
in "all broad cell line expression data.zip" online)
For analysis, the dataset was further processed as follows: 1) The -22K total probe sets
on the Affy U133A were restricted to the 9084 judged expressed (p-value<0.06) by the
Affymetrix software in at least 2/3 of 50 randomly selected scans. 2) These 9084
expressed probes were matched by Genbank transcript accession number (NM_#) to the
13,300 targets judged expressed by the same criterion in the WTSI Illumina HapMap
experiments. (using the probability of detection p-value output by the Illumina software.)
This yielded a reduced set of 3600 Affy probes (3592 Illumina targets) whose transcripts
were reliably detectable in both experiments. 3) To obtain a comparable dataset from the
WTSI Illumina data, we took the median over their 4 technical replicates for each target
and quantile normalized across all samples. 4) We averaged within each gene symbol, in
each dataset, for each sample, to get the set of 3538 genes expressed in both experiments
and measured on both platforms. 5) To prevent family structure from introducing bias,
the dataset was restricted to unrelated individuals only for the analyses in Figures 3-6:
198 each in the main Broad and WTSI experiments, 49 biological replicates at the Broad,
and 16 samples for whom RNA was extracted at the WTSI and measured in both
locations. Both centered (for each gene within each panel) and uncentered data is
available in "cleaned expression data used in analyses.zip" and were each used as
appropriate.
Relative EBV and mtDNA Copy Number
All previously collected DNA was diluted to PCR concentration of 2.5 ng/uL and arrayed
in 384 well storage plates (AbGene Cat No. AB-0564). Custom TaqMan assays were
designed using Primer 3 (http://frodo.wi.mit.edu/) and ordered from Applied Biosystems.
The EBV copy number assay interrogated a 66_bp fragment at the DNA polymerase
locus (EBV forward primer 5'GACGA TCTTGGCAATCTCT3', EBV reverse primer
5'TGGTCATGGATCTGCTAAACC3', EBV probe 5'6FAM-
CCACCTCCACGTGGATCACGA-MGBNFQ3'). The mtDNA copy number assay
examined a 72 bp fragment at the ND2 locus (mtDNA forward primer
TGTTGGTTATACCCTTCCCGTACTA, mtDNA reverse primer
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CCTGCAAAGATGGTAGAGTAGATGA, mtDNA probe sequence 5'6FAM-
CCCTGGCCCAACCC-MGBNFQ3').
As an internal reference, a 90bp assay from the NRF 1 locus on chromosome 7 was
multiplexed with EBV or mtDNA (NRFI forward primer
5'CTCGGTGTAAGTAGCCACAT 3', NRF1 reverse primer
5'GAGTGACCCAAACCGAACAT 3', NRF1 probe 5'VIC-
CACTGCATGTGCTTCTATGGTAGCCA-MGBNFQ 3'). Equal efficiency of
amplification was observed for each assay in the multiplex reaction. Final Concentrations
for EBV primers, mtDNA primers, EBV probe, mtDNA probe, NRF1 primers and NRF1
probe were .25 uM, .25 uM, 10uM, 10uM, luM and 10uM respectively. 5ng of DNA
template was used for each TaqMan reaction performed according to the manufacturer's
protocol. Relative EBV and mtDNA copy number was determined by the difference of
CT method 38. Log-transformed. EBV measurements were obtained when cell lines were
first received from Coriell (257), during the main batch of experiments (257), and for the
biological replicate set (86). Mitochondrial DNA measurements were obtained only for
252 cell lines in the main experiments.
Fraction of RNA variance explained by cellular phenotype or eQTL
(Figure 4)
We are interested in the fraction of gene-trait (or gene-eQTL) relationships that are real
(i.e. would reach statistical significance given enough samples) and above a given r"2
(rhoA2) thresh-hold in the current sample. So, we want P(real, r2 >= c) in joint
distribution notation, i.e. a relationship can be real (non-null) or spurious (null) and can
exceed a certain threshold or not. By regressing a trait on multiple genes, we observe:
P(r2 >= c). It is the fraction of relationships exceeding any given threshold, the green
curve. By permutation, we also have: P(r2 >= c I not _ real), the blue (average of black)
curve. So, we write, by conditioning on whether a relationship is real or not:
P(r 2 >= c) =
= P(r 2 >= c Ireal)P(real) + P(r 2 >= c Inot - real)(1 - P(real))
= P(real, r 2 >= c) + P(r 2 >= c not _ real)(1 - P(real))
Or, rewriting, we have:
P(real, r 2 >= c) = P(r2 >= c) - P(r2 >= c not _ real)(1 - P(real))
Everything on the right hand side is known, except P(real), the true proportion of gene-
trait relationships in the data. This can theoretically be estimated ala Storey et al. 2003 39
but the estimate can be unreliable in the setting of dependencies, as is the case in our data
since genes are largely in clusters. So, we take the worst case scenario, setting P(real)=0.
Thus, we have:
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P(real, r2 >= c) 2 P(r2 >= c) - P(r2 >= c I not _ real)
So, P(r 2 >= C) - P(r 2 >= c I not _ real) is then a lower bound for P(real, r >_ c),
the black curve. It is important to note that the interpretation of this lower bound is
limited to the sample size used in the analysis. Given more samples, the estimate will
change to even more genes being affected by traits or eQTLs, albeit at lower rA2s.
Decomposing gene expression into inter- and intra- components(Figure 5)
To estimate the amount of inter- and intra- individual variation present for each gene in
the -50 unrelated individuals thawed and measured twice at the Broad Institute, we fit a
random effects model of the form y, = u + a, + ,U , where i indexes the individuals, and
j is 1 or 2 for the biological replicate being considered. The estimated variance
2
component 0• is then the inter-individual variation in gene expression for the gene,
2
while the residual variance Uo is the intra-individual variation. To evaluate the effect of a
cis-eQTL or cellular phenotype on an RNA, a fixed effect x corresponding to trait was
then added to the model to get: y, = p + fix, + a, + co . The resultant change in variance
2 2
components oa and o' can then be interpreted as the "effect" of that trait or snp on
RNA expression. The directionality of the effect is clearly only known for SNPs, but the
nature of relationship (inter-, intra-, or both) can be examined for any trait. It's worth
pausing to reflect on what these "effects" mean: If including a QTL SNP genotype in the
model reduces inter-individual variance (as the overwhelming majority of SNPs do, Fig
5a), it implies that fixed differences in genotypes (QTLs) between individuals correlate to
fixed differences in expression between individuals in the corresponding gene. (as one
would expect) If, on the other hand, the intra-individual variance component is reduced
when accounting for a given trait, the implication is that day-to-day variations in the trait
correspond to day to day variations in the RNA. As would be expected, some genes also
show a combination of the two effects. Finally, these estimates are quite noisy, suffering
from random fluctuations in RNA levels, measurement error, and the relatively small
sample size available for the analysis; estimation is likely even less reliable for weaker
effects. Nevertheless, the analysis is instructive for the stronger signals and overall
patterns and would improve given more samples and technical replicates.
GWAS for drug response
1,045,141 autosomal SNPs with MAF>10% in each of the 3 (CEU, YRI, CHB/JPT)
HapMap panels were selected from the Phase 2 HapMap build 21 for association testing
to drug response phenotypes. The between/within family model of association was tested
for each SNP against each drug, in each panel independently, using PLINK32 vl.02 with
options "--qfam-total --geno 1 --aperm 100 100000000 0.00000005 0.0001 5 0.001". For
each drug, p-values for each SNP were then combined across panels using Fisher's
method. 25,735 X-chromosome SNPs were tested analogously, but using an additive
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model on unrelated individuals only with PLINK command line "--assoc --geno I"; none
exceeded 5e-8. QQ plots for the autosomal SNPs for each drug are available at:
http://www.broad.mit.edu/-yelensky/cell linesjpaper/snpsvs-drugresponsepvalues/.
R - Aside from GWAS scans performed using PLINK, all other analyses were performed
using R version 2.5.040.
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RNA Expression Drug Response
Measurement: mRNA micro-arrays drug perturbations and readouts
Figure 1: Genetic and Non-genetic Factors influencing lymphoblastoid cell lines as a model system to
understand human physiology. i
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Figure 2: Drug response is correlated across multiple drugs, to growth rate and to baseline ATP
levels of the cell line.
(A) Relative drug responses were calculated for each individual as described in Methods to obtain a
single number summary of the cell line response to each drug oji each day. The black circles
represent an individual cell line's relative response to 6MP assayed on day one plotted against
6MP relative response assayed on day two. The red circles similarly represent relative response to
6MP plotted against relative response to MTX, both assayed on day one. The green circles
represent relative response to 6MP plotted against relative response to 5FtJ, again both assayed on
day one. Lines represent regressions for each of the three comparisons and show that not only is
relative drug response a reproducible trait, but also can be correlated across multiple drugs.
(B) Using online data made publicly available by Watters et al. 25, relative drug response to docetaxel
and 5FU was calculated using the 427 individuals with no missing data to obtain a single number -
for each drug, in each individual, as in (A). Response to docetaxel was plotted against 5FU for
each individual. The line represents the regression for the comparisqn and indicates that the effect
observed in (A) is neither limited to our experiments, nor to the particular drugs we attempted.
(C) The baseline growth-rate of each individual's cell line was estimated as described in the Methods.
This growth rate is plotted against relative response for 6MP (black), MTX (red), and 5FU
(green). Lines represent regressions for the respective comparisons and all correspond to
significant correlations.
(D) For each individual, baseline ATP levels were measured using Celltiter glo in the m6ck-treated
wells in drug response assays. EC50 response was calculated correcting for growth rate (see
Methods). Relative ATP levels were plotted against the growth-rate corrected EC50 for MTX
(red), and 5FU (green). Lines represent regression for the comparisons and indicate significant
correlations.
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(D).
(D) The analysis for the brown and green curve in (C) is repeated only for 
the 1000 "best-measured"
genes and plotted in magenta and cyan respectively. Plot shows 
that even if measurement noise is
limited, a substantial portion of the variance in gene expression 
represents biological noise.
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Figure 3: Biological variation in RNA expression
49 unrelated individuals were whole-genome 
RNA profiled
on the Affymetrix platform in two independent 
experiments at
the Broad Institute. (same-platform biological replicates) A
subset of 14 (of the 49) were also profiled independently at
the WTSI on the Illumina platform (cross-platform biological
replicates) and an aliquot of that RNA ("WTSI RNA") was
again profiled at the Broad Institute on the Affymetrix
platform. (cross-platform technical replicates)
(A) Expression values of all 3538 expressed genes were
ranked in each of the 14 unrelated individuals in 
the
two Broad Institute biological replicate experimentg
and ranks were compared between: the same
individuals in two separate experiments (black); all
pairs of unrelated individuals across two
experiments (red); 5 chimpanzees assayed in the
first experiment and all individuals assayed in the
second experiment (blue). Plot shows that overall
expression profiles in LCLs are highly similar 
across
biological replicates, between unrelated individuals,
and even across species.
(B) The 49 individuals were ranked according to their
relative levels of each gene in the first Broad
experiment. The ranking was then independently
repeated for the second Broad experiment. Ranks
were compared across the two experiments for each
gene and the results plotted in (green), with the
median of the distribution in (dotted green). Plot
shows that when any given gene is examided, there
is substantial variation in the relative order of
individuals between two independent experiments,
despite the relative order of genes being highly
stable as shown in (A). Light black and red lines are
same as (A) for comparison.
(C) On the set of 14 individuals, per-gene rank
comparisons as in (B) are computed for: WTSI RNA
assayed on the Illumina platform vs. WTSI RNA
assayed on the Affymetrix platform (gold solid and
dotted); WTSI RNA assayed on the Illumina
platform vs. RNA extracted at the Broad Institute
during the first experiment and assayed on the
Affymetrix platform (brown solid and dotted); the
two independent Broad experiments as in (B), (green
solid and dotted). Plot shows substantial biological
variation in the relative levels of any given gene
when profiling experiments are repeated, far in
excess of that might be expected from measurement
error alone. Magenta dash indicates the cut-off for
the 1000 "technically best-measured" genes to use in
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(A) For each tested gene, Broad RNA expression levels were rank-correlated to copy numbers of
EBV, as determined by quantitative PCR. The correlation was expressed as rho^2 and curves
representing distributions of the rho^2 values are plotted. The green curve is the observed
distribution of EBV-RNA correlations. The red curves represent 20 permuted distributions. The
blue curve is the average of permuted distributions. The black curve is the difference between
observed and permuted values and thus a lower bound (see Methods) of the fraction of genes
correlated to EBV at a given rhoA2. Plot shows that -15% of expressed genes have >5% of their
(rank) variance in expression explained by EBV levels.
(B) For each tested gene, Broad RNA expression levels were correlated to baseline ATP levels
determined by measuring Celltiter glo in mock-treated wells in the drug response assays. Curves
representing the distribution of rho^2 values were plotted for the tested genes as in (A). Plot
shows that >25% of expressed genes have >5% of their variance in expression explained by ATP
levels.
(C) For each tested gene, Broad RNA expression levels were correlated to all SNPs with MAF>10%
within a 0.15Mb window around the gene, using the HapMap phase II data. Curves representing
the distribution of the largest r^2 value was plotted for each tested genes as in (A). Plot shows that
>9% of genes have >5% of their variance in expression explained by SNPs in the Broad RNA
dataset.
(D) For each tested gene, Sanger RNA expression levels were correlated to all SNPs with MAF>10%
within a 0.15Mb window around the gene, using the HapMap phase II data. Curves representing
the distribution of the strongest rA2 value was plotted for each tested genes as in (C). Plot shows
that >20% of genes have >5% of their variance in expression explained by SNPs in the WTSI
RNA dataset.
(E) For each tested gene, Broad RNA expression levels were correlated to EBV, growth rate, and
relative ATP, and the strongest observed correlation among the 3 phenotypes was plotted.
Strikingly, plot shows that >40% of genes have >5% of their variance in expression explained by
one of these covariates.
(F) For each tested gene, WTSI RNA expression levels were correlated to EBV, growth rate, and
relative ATP, and die strongest observed correlation among the 3 phenotypes was plotted.
Strikingly, plot shows that the effect of covariates in.(E) is observable even when looking at a
completel'y separate expression experiment, performed independently of covariate collection.
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Figure 5: Contributions by eQTLs, EBV, and ATP to inter- and intra -individual variation in RNA
expression levels, and contributions by RNA expression levels to inter- and intra- individual
variation in drug response.
Total variance for each of the 1000 "best-measured" genes was separated into inter- and intra- individual
variance components (see Methods) using expression data from the 49 unrelated individuals measured
twice at the Broad Institute on the Affymetrix platform.
(A) 95 genes with eQTLs that explained >10% of expression variance (FDR<10%) in the WTSI
dataset were selected (to maximize eQTL detection power) and the SNP genotype was included in
the variance components model of the gene to "account" for its effect. -1 times the change in each
variance component is plotted for each gene. As expected, the plot shows that that SNPs (which
remain fixed across experiments) only explain inter-individual variation in expression. Grey
dashed lines indicate the inter- and intra- 2.5% and 97.5%-tiles of the distribution of variance
component change estimates when the entire analysis is repeated on a permuted dataset.
(B) 125 genes correlated to EBV at rhoA2>.05 (FDR<10%) were selected and the EBV
measurement was included in the variance components model of the gene to "account" for its
effect. -1 times the change in each variance component is plotted for each gene. The plot shows
that EBV can contribute to inter-individual differences in gene expression that persist across
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experiments, intra-individual fluhictuation in gene expression between experiments, or both,
depending on the gene in question. Grey dashed lines are as in (A).
(C) 249 genes correlated to ATP at rhoA2>.05 (FDR<10%) were selected and the ATP
measufement was included in the variance components model of the gene to "account" for its
effect. -1 times the change in each variance component is plotted for each gene. The plot shows
that ATP can contribute to inter-individual differences in gene expression that persist across
experiments, intra-individual fluctuation in gene expression between experiments, or both,
depending on the gene in question. Grey dashed lines are as in (A).
(D) 202 "drug-response correlated" genes were defined as in Figure 6. The expression of each
gene was incorporated in a variance components model of the assigned drug response EC50 to
examine the contribution of the gene to its strongest correlated drug. -1 times the change in the
variance components of drug response is plotted for each gene, showing that it is mostly the inter-
individual differences in gene expression that are correlated to tell line drug response. Grey
dashed lines are as in (A).
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Figure 6: Effect of cis-eQTLs in drug-response correlated genes on drug-response
The 198 unrelated individuals were ranked by RNA expression value for each of the 1000 "best-measured"
genes. These individuals were then ranked by response (growth/ATP- corrected EC50) to each of the 5
assayed drugs. Rank-correlations (spearman's rho) were computed for each gene-X-drug pair (1000x5)
and the drug with the strongest correlation to a given gene was "assigned" to that gene. The 202 genes
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whose strongest drug correlations exceeded rho^2=.05 (FDR<10%) were taken as "drug-response
correlated" genes. If such a gene also had a cis-eQTL that explained at least 8% (FDR<10%) of its
variance, the tuple SNP-RNA-Drug was considered in the foregoing panels. We considered 23 tuples (14
derived using WTSI RNA dataset + 9 derived using the Broad Institute RNA dataset)
(A) Diagram of different classes of influences on drug response and RNA levels. Solid arrows
represent correlation due to a causal effect.
Coding SNPs have direct (non-RNA mediated) effects on drug response by altering protein
function. No SNPs of this class were found at genome-wide significance in our GWAS scan.
Changes in RNAA directly cause changes in drug response. An
eQTL for one of these RNAs (i.e. eQTLA) is thereby causal for drug response.
Non-genetic confounding factors simultaneously influence RNAB levels and drug response
and changes in RNAB do not cause changes in drug response (this is the expected scenario for
most RNAs). If levels of these RNAs are affected by eQTLs, these eQTLs cannot be causal
for drug response (the eQTLB effect on RNAB and the RNAB relationship to drug response
are orthogonal).
Our goal in mapping true RNAs and eQTLs causal for drug response is to distinguish eQTLA
and RNAA from eQTLB and RNAB.
(B) For each tuple (WTSI - red, Broad - green) the drug response was regressed against the eQTL
SNP genotype. P-values are plotted as open circles against their expectation under the null.
Black solid line indicates the theoretical flat uniform distribution expected under the null and
black dashed line is the p=.05 one-sided significance threshold for deviation from the null.
Grey lines show equivalent null parameters, but derived from a simulated dataset with the
same SNP/RNA/Drug variances and independent SNP-RNA/RNA-Drug pairwise
covariances as the real 23 tuples. Plot shows that the observed p-value distribution for drug-
response regressed against RNA eQTL SNPs deviates significantly from null, suggesting that
some RNA relationships to drug response and corresponding SNP relationships to RNA are
not orthogonal. (and thus possibly causal)
(C) For each tuple, simulated datasets were created with the same SNP/RNA/Drug variances and
RNA-Drug pairwise covariance as the real 23 tuples, but with the real SNP-RNA
covariances replaced by r^2=0.05. Then, only those simulations where the observed SNP-
RNA association exceeded r^2=0.08 were used to plot the median and p=.05 SNP-Drug p-
value distributions as in (B) (again, grey solid and grey dashed lines, respectively). Black
lines also as in (B). Plot shows that "winner's curse" in eQTL discovery leads to an inflation
of SNP-Drug associations, in the absence of any real causal relationship between RNA and
Drug response (and thus, SNP and Drug).
(D) For each tuple (WTSI - red, Broad - green), the correlation between SNP and RNA is
plotted against the correlation between SNP and Drug. Most increased association between.
SNP and Drug response comes from the weaker eQTLs, while most of the stronger eQTLs
have no association to drug response, consistent with the winner's curse phenomenon
displayed in (C). Additionally, 3 interesting tuples emerge that are both relatively strong
SNP-RNA and SNP-Drug response associations, indicated by the light blue arrow.
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0o -Supplementary Figure SI: Direction of
0• O SNP-Drug response association
O  O For each tuple (WTSI - red, Broad - green)
. ,- in Figure 6, the product of the correlation (r)
SO between SNP and RNA and the correlation
(rho) between RNA and Drug is plottedSO against the correlation (r) between SNP and
ci Drug. Black lines separate the plot into the 4
0 quadrants. Gray dotted lines show the
O O N expected distribution of associations
8 between SNP and Drug under the "null"
I model simulated in Figure 6B. Plot shows
that the direction of association SNP-Drugi C93  response tends toward the direction
0 1. predicted from the directions of the SNP-
-0.2 -0.1 0.0 0.1 0.2 RNA and RNA-Drug correlations (i.e. if the
major allele drives the RNA up and more
snp-ma correlation * ma-drug correlation RNA makes the cell-line more sensitive to
drug, then the major allele should make the
cell-line more sensitive to drug). This tendency would not be expected by chance alone.
Supplementary Figure S2:
Winner's curse: 198 samples, detection at r^2=0.08 Winner's curse in eQTL
discovery
$ ayverage bias Simulations were performed too5 • std dev of bias
.a demonstrate that effect sizes of
-J
O weaker eQTLs are overestimated,
" on average. Specifically, for effect
0 sizes (rA2) between 0.01 and 0.50,
S100,000 datasets of 198 values each
S------ (corresponding to the sample size
of the analysis in Fig 6) were
E simulated from a bivariate normal
" Bdistribution with mean=(0,0),
.0 / variances=(1,1) and
-w covariances=sqrt(effect size).
" / o Datasets with observed correlation
oi (rA2)>0.08 were then considered:
0o. For each simulated effect sizes, the
,o average difference (bias) between
o °-o- °---o o the observed and simulated effect
o , size is plotted, together with the
0.0 0.1 0.2 0.3 0.4 0.5 standard deviation of the
distribution of differences. Plot
true simulated QTL effect size (r^2) distribution of differ eQTLs areshows that weaker eQTLs are
usually over-estimated, even for true effects that are above the detection threshold. On the other hand,
estimates of effect sizes of stronger eQTLs are unbiased, on average.
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Compound
MTX
5FU
6MP
Simva
Saha
velcade
rapa
Compound
MTX
5FU
6MP
Simva
Saha
rho
0.98831
0.97217
0.94395
0.91629
0.85846
0.88812
0.91968
rho
0.82
0.63
0.66
0.39
0.71
rho^2
0.976749
0.945105
0.891043
0.839582
0.736949
0.788753
0.845818
rho^2
0.67
0.39
0.43
0.15
0.50
pval
<2.20e-16
<2.20e-16
<2.20e-16
<2.20e-16
<2.20e-16
<2.20e-16
<2.20e-16
pval
1.2E-15
6.6E-08
9.7E-09
2.OE-03
2.0E-10
Supplementary Table 1
Supplementary Table 2
Rlative Drug
MTX
6MP
5FU
MTX 6MP 5FU Simva Saha
2.20E-16 1.14E-08
2.20E-16 7.44E-05
0.78 0.61
Simva 0.36
Saha 0.16
pvalues <.001 marked in red
0.25
0.2
Supplementary
Table 3
0.00977
0.00127
1.26E-06
1 97E-04
0.3 0.23
Correlation to Growth Rate of relative drua response
Drug . MTX 6MP 5FU Simva Saha
Rank Correlation -0.34 -0.31 -0.3
P-value 1.86E-07 3.21E-06 7.61E-06
pvalues <.001 marked if) red
-0.15 0.04
0.031 0.603
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Growth-
corrected EC60
Druag Resonae MTX 6MP 5FU Simva Saha
1.74E-09 2.27E-1 1MTX
6MP
0.174
Supplementary
Table 4
0.0165 0.973 0.0524
5FU
Simva
Saha
pvalues <.001 marked in
0.37 0.15
0.41 0.0021
1.54E-04
0 118
0.09 0.12 0.24
Correlation to Growth Rate of EC60/Growth-corrected drug responses
Drug MTX 6MP 5FU Simva Saha
Rank Correlation -0.1 0.06 -0.24 -0.14 0.06
P-value 0.14 0.4 0.00034 0.0356 0.345
pvalues <.001 marked in red
Growth and
ATP-Cortrctsd
Dru RMesmonse MTX 6MP . 5FU Simva Saha
Supplementary
Table 5
n 041 0008
6MP 0.15
5FU 0.19
Simva 0.40
Saha -0.03
pvalues <.001 marked in red
. 3
0.003 0.973 0.052
0.0060.22
0.00 0.
0.12 0.20 0.10
127
MTX 2.06E-08 0.703
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Chapter 7: Summary and Discussion
The "ideal world" for a human geneticist, where we have the full sequence of
every individual under study, where we know the expression, post-translational
modification, and localization of every gene in every cell, and where we can safely
perform in-vivo perturbation experiments and measure all relevant changes in physiologic
state is still many years away. In the mean-time we must rely on useful and practical
proxy genotypes and phenotypes to enable discoveries in human biology using the
genetic mapping approach. This thesis presents one important class of proxy genotypes,
those that capture most common genetic variation, as well as an evaluation, refinement
and application of proxy phenotypes offered by a commonly used in-vitro model, the
lymphoblastoid cell-line.
To develop a useful proxy for the full sequence, we investigated the selection and
analysis of tag SNPs for genome-wide association studies: specifically, the relationship
between investment in genotyping and statistical power. Do pair-wise or multi-marker
methods maximize efficiency and power? To what extent is power compromised when
tags are selected from an incomplete resource such as HapMap? We examined these
questions using genotype data from the HapMap-ENCODE project, association studies
simulated under a realistic disease model, and empirical correction for multiple
hypothesis testing. Perhaps most impressively, we found that simply picking 1 SNP every
10kb at random from a complete map (in the CEU panel) provides >80% of the power to
detect common causal variants as does genotyping all common variants directly. Even
simple single-marker tagging/testing approaches can provide -90% power with 1 tag per
5kb or less. We then demonstrated a haplotype-based tagging method that uniformly
outperforms single-marker tests, and methods for prioritization that dramatically increase
tagging efficiency further. Examining all observed haplotypes for association - not just
those that proxy for a known SNP - increases power to detect rare causal alleles, at a
cost of reduced power for common causal alleles. Power is surprisingly robust to the
completeness of the reference panel from which tags are selected.
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Practically, tag SNPs are chosen from data in one population sample (i.e.
HapMap) and then deployed in another sample (the disease study cohort). Thus, it is also
important to know how well tags picked using the HapMap capture the variation in other
samples. To address this, we collected dense data uniformly across the four HapMap
population samples and eleven other population samples. We picked tag SNPs using
genotype data we collected in the HapMap samples and then evaluated the effective
coverage of these tags in comparison to the entire set of common variants observed in the
other samples. We simulated case-control association studies in the non-HapMap samples
under the same disease model of modest risk as above, and observed little loss in power.
These results demonstrated that the HapMap DNA samples can be used to select proxy
genotypes for genome-wide association studies in many samples around the world.
As many investigators will rely on commercially available "whole genome"
arrays for their GWAS, we also evaluated the extent to which the sets of SNPs contained
on three widely used products capture common variation across the genome. We found
that the majority of common SNPs are well captured by these products either directly or
through linkage disequilibrium. (this was particular true for technologies designed with
tagging principles in mind) We then explored analytical strategies that utilize HapMap
data to improve power of association studies conducted with these fixed sets of markers,
and show that inclusion of our specific haplotype tests in association analysis can
increase the fraction of common variants captured by 25% to 100%. This idea was later
expanded by others into a full multi-point imputation approach that is now a mainstay of
association studies world-wide. '
Given that most common variation is thus being captured and that much of the
variation is correlated, it became important to estimate the number of independent tests
implicit in a complete common-variant GWAS for purposes of simple and accurate (i.e.
Bonferroni) multiple-testing correction and evaluation of nominal association results.
Applying our simulation framework to the problem, we found that GWAS for common
(MAF>5%) variants correspond to -500,000 independent tests in out-of-Africa and
-1,000,000 tests in African samples, implying a reasonable genome-wide significance
threshold for declaring association of roughly 5e-8. This threshold was confirmed by
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others 2 (as well as predicted by Risch and Merikangas in 1996!) and is now commonly
accepted and widely used.
Taken together, our work shows that it is possible and practical to
comprehensively determine the common variant contribution to disease by employing a
well-chosen set of genotypes and analytical approaches that can proxy for all or nearly
common genetic variation in the genome. Although our investigation was primarily
focused on variants with MAF>5%, nothing in principle restricts the applicability of our
findings to variants with lower frequency. All that is required are sufficiently sized
cohorts for the discovery of variants and assessment of LD. With the commencement of
the 1000 Genomes Project 3, these resources will soon be in hand, setting up an even
bigger wave of medical genetic discoveries. The tools and methods we devised, together
with the theoretical/empirical understanding of LD-based genome-wide association
we've obtained, will no doubt facilitate this advance.
Identification of a genetic variant in a genome-wide scan is, of course, only the
beginning of the process to elucidate its function, place it in context of other genetic and
non-genetic variation, and understanding the relevant physiology. As it is important to
elucidate the functional effects of a mutation "proximally" to the mutated site, geneticists
must seek to obtain phenotypes from the relevant cells, tissues, or systems. Because it is
difficult to obtain (all but routine clinical) phenotypes from human subjects, and because
most informative perturbation experiments in human beings are impossible, geneticists
often rely on in-vitro or ex-vivo models to proxy for in-vivo genetics and physiology.
Lymphoblastoid cell lines (LCLs), originally collected as renewable sources of
DNA, are now being used as one such model to study genotype-phenotype relationships
in human cells. These cell lines have been used to search for genetic variants that are
associated with drug response as well as with more basic cellular traits such as RNA
levels. In setting out to extend such studies by searching for genetic variants contributing
to drug response, we observed that phenotypes in LCLs were, in our lab and others,
significantly affected by experimental confounders (i.e. in vitro growth rate, metabolic
state, and relative levels of the Epstein-Barr virus used to transform the cells). Even after
correcting for these confounders, we did not find any SNPs associated with genome-wide
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significance to drug response. We also evaluated whether incorporating RNA expression
levels (and eQTLs) in the analysis could increase power to detect such effects. As
previously shown, cis-acting eQTLs were detectable for a sizeable fraction of RNAs and
baseline levels of many RNAs predicted response to drugs. However, we found only
limited evidence that SNPs influenced drug response through their effect on expression of
RNA; nevertheless, it remains possible that integrating SNPs, RNA, and drug response
can identify novel pharmacogenetic variation mediated by RNA. Efforts to use LCLs to
map genes underlying cellular traits will require great care to control experimental
confounders, unbiased methods for interpreting such multi-dimensional data, and much
larger sample sizes than have been applied to date.
Our experience with lymphoblastoid cell-lines is likely general and applies to
other in-vitro models, including those that don't yet exist. Indeed as it becomes possible
to reprogram any adult cell-type into stem-cells 4' 5 and then re-differentiate these into any
tissue, the applicability of proxy models to genetic mapping will only increase. Imagine,
for instance, the impact that fully functioning beta-cells with specific genotypes at
diabetes risk-conferring sites would have on untangling pathophysiology and designing
targeted interventions. The challenge, as our study demonstrated, will be to detect and
control for extraneous sources of phenotypic variation so that the subtle genetic
differences we are interested in can emerge.
In all branches of science, from astronomy, to geology, to chemistry, reality can
rarely be directly observed. Progress is often determined by the characterization and
application of indirect measurements that reflect (or proxy for) some useful aspect of
reality. This thesis presents proxy measurement (genotypes and phenotypes) for one
subfield of biology, medical genetics. At the same time, it lays out the principles and
methods for the development of further proxy measurements of this class. Together, it is
hoped that our findings will enable discoveries today and facilitate medical genetic
research yet to come.
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